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0.5 – ABSTRACT 
0.5 – Abstract 
Progression of atherosclerosis and thrombosis in patients at risk of cardiovascular 
disease depend heavily upon the unique physical and biochemical environment of 
each individual. Characteristics such as vessel architecture, biochemical composition 
of blood or type of treatment define the outcome of cardiovascular interventions. 
Stent placement and graft positioning seek to recover vessel patency, yet are limited 
by restenosis and thrombosis. Composite, patient-specific, multi-scale models able to 
integrate microscopic cellular responses in the context of relevant macroscopic flow 
and structural conditions may help understand the progression of these events, 
providing insight into how to mitigate adverse responses in specific settings and 
individuals. Based on previously validated in silico and in vitro methods, an arterial 
replication platform was developed. Vascular architectures from coronary and carotid 
bifurcations were derived from clinical imaging and used to generate conjoint 
computational meshing for in silico analysis and polymeric, biocompatible scaffolds 
for in vitro models. In parallel with three dimensional flow simulations, the 
geometrically-realistic constructs were seeded with vascular cells critical to vessel 
hemostasis and response to injury and exposed to relevant, physiologic flows and 
uremic, inflammatory or anti-proliferative conditions. Following functional 
characterization, in vitro surrogates of atherosclerotic and thrombogenic progression 
were locally quantified and correlated with the biological, chemical and physical 
characteristics of the cellular environment. The extent of recirculation and the 
presence of inflammatory agents, anti-proliferative chemicals and uremic serum and 
solutes were critical to the activation of atherosclerosis and thrombosis progression 
biomarkers. Integrated frameworks such as the one described in this thesis could be 
very useful in a range of biomedical fields. The platform may help researchers to 
answer an array of biological and clinically relevant questions and holds the capacity 
to cast bioimplantable vascular grafts in a close future. 
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0.5 – ABSTRACT 
La progresión de la aterosclerosis y la trombosis en pacientes con riesgo de 
enfermedad cardiovascular depende en gran medida del entorno único a nivel físico y 
bioquímico de cada individuo. Características tales como la arquitectura de la 
vasculatura, composición bioquímica de la sangre o el tipo de tratamiento definen el 
resultado de las intervenciones cardiovasculares. La colocación de un stent o de un 
bypass busca recuperar la permeabilidad del vaso, pero se ve limitada por la restenosis 
y la trombosis. El diseño de modelos multi-escala específicos para cada paciente 
puede ayudar a entender la progresión de estos eventos al tener capacidad para 
integrar las respuestas celulares microscópicas en el contexto del flujo macroscópico 
y de las condiciones estructurales. Dichos modelos pueden proporcionar información 
sobre cómo mitigar respuestas adversas en función de cada individuo. Usando 
métodos in silico e in vitro previamente validados se ha desarrollado una plataforma 
de replicación arterial para reproducir bifurcaciones vasculares coronarias y carótidas 
derivadas de imágenes clínicas, que se han usado para generar archivos 
computacionales para análisis in silico por un lado y para fabricar modelos arteriales 
poliméricos biocompatibles para análisis in vitro por otro. En paralelo con las 
simulaciones de flujo, los modelos físicos fueron sembrados con células vasculares 
centrales en la hemostasia y la respuesta a las lesiones. Los modelos vasculares fueron 
expuestos a flujos fisiológicos relevantes y a entornos urémicos, inflamatorios o 
anti-proliferativos. Tras la caracterización funcional de los modelos, el progreso de la 
aterosclerosis y la trombosis se cuantificó a nivel local y se correlacionó con las 
características biológicas, químicas y físicas del entorno celular. La cantidad de 
recirculación y la presencia de agentes inflamatorios, productos químicos 
anti-proliferativos y de suero y solutos urémicos fueron críticos para la activación de 
los biomarcadores de evolución de aterosclerosis y trombosis. Plataformas integradas 
tales como la descrita en esta tesis podrían ser muy útiles en una variedad de campos 
de la biomedicina. La plataforma puede ayudar a los investigadores a responder una 
serie de cuestiones biológicas clínicamente relevantes y tiene la capacidad de producir 
injertos vasculares bioimplantables en un futuro próximo. 
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0.5 – ABSTRACT 
La progressió de l'aterosclerosi i la trombosi en pacients amb risc de malaltia 
cardiovascular depèn en gran mesura de l'entorn únic a nivell físic i bioquímic cada 
individu. Característiques tals com l'arquitectura de la vasculatura, la composició 
bioquímica de la sang o el tipus de tractament defineixen el resultat de les 
intervencions cardiovasculars. La col·locació d'un stent o d'un bypass busca recuperar 
la permeabilitat del vas, però es veu limitada per la restenosis i la trombosi. El disseny 
de models multi-escala específics per a cada pacient pot ajudar a entendre la 
progressió d'aquests esdeveniments en tenir la capacitat per integrar les respostes 
cel·lulars microscòpiques en el context del flux macroscòpic i de les condicions 
estructurals. Aquests models poden proporcionar informació sobre com mitigar 
respostes adverses en funció de cada individu. Emprant mètodes in silico i in vitro 
prèviament validats, s'ha desenvolupat una plataforma de replicació arterial per 
reproduir bifurcacions vasculars coronàries i caròtides derivades d'imatges clíniques 
que s'han fet servir per generar arxius computacionals per a anàlisi in silico per una 
banda i per fabricar models arterials polimèrics biocompatibles per a anàlisis in vitro 
de l’altra. En paral·lel amb les simulacions de flux, els models físics van ser sembrats 
amb cèl·lules vasculars centrals en l'hemostàsia i la resposta a les lesions. Els models 
vasculars van ser exposats a fluxos fisiològics rellevants i a entorns urèmics, 
inflamatoris o anti-proliferatius. Després de la caracterització funcional dels models, 
el progrés de l'aterosclerosi i la trombosi es va quantificar a nivell local i es va 
correlacionar amb les característiques biològiques, químiques i físiques de l'entorn 
cel·lular. La quantitat de recirculació i la presència d'agents inflamatoris, productes 
químics anti proliferatius i de sèrum i soluts urèmics van ser crítics per a l'activació 
dels biomarcadors d'evolució d'aterosclerosi i trombosi . Plataformes integrades tals 
com la descrita en aquesta tesi podrien ser molt útils en una varietat de camps de la 
biomedicina. La plataforma pot ajudar els investigadors a respondre una sèrie de 
qüestions biològiques clínicament rellevants i té la capacitat de produir empelts 
vasculars bioimplantables en un futur pròxim. 
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The endothelium, a monolayer of endothelial cells (EC) that lines the inner surface of blood 
vessels, is exposed to a complex biomechanical milieu (Figure 1, Figure 2). EC are responsible 
for relaying biochemical messages regulators that ensure blood fluidity, nutrient transport and 
an appropriate control of coagulation to the underlying tissue and flowing blood. In the 
presence of local injury, the smooth muscle cell (SMC) multilayer becomes exposed to flow 
and interactions between EC and SMC in the presence of hemodynamic forces lead to a 
cascade of reactions that modulate vessel patency, promote low-density lipoprotein 
internalization, cell adhesion molecular expression, monocyte adhesion and tissue factor 
expression. EC-SMC crosstalk and their interactions with the local environment has been the 
subject of research for several years. Within the realm of understanding the impact of flow 
and vascular repair due to injury, previous work focused on developing bench-top model 
systems to examine the differences in EC biology in the presence and absence of SMC and 
understanding the regulatory interaction between alterations in hemodynamics and the 
vessel wall.  
 




Figure 2 - Cross section of an artery A= EC, 
B= Elastin, C= SMC, D = Adventitia 
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While it is known that EC are especially sensitive to flow, the focus in these studies lacked the 
sophistication to truly replicate the physiologic environment of the vasculature. Over the last 
decades, biomedical engineers, in collaboration with physicians, biologists, chemists, 
physicists and mathematicians, have developed models to explain how the impact of vascular 
interventions on blood flow predicts subsequent vascular repair and other biological 
responses2. These models have become increasingly sophisticated and precise, propelling us 
toward optimization of cardiovascular therapeutics in general and personalizing treatments 
for patients with cardiovascular disease and its most common cause: atherosclerosis. In this 
thesis, vessel-like bench-top constructs were designed to evaluate the underlying 
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1.1 – Effects of flow disruptions 
Blood vessels are constantly exposed to various types of hemodynamic forces, such as 
hydrostatic pressure, cyclic stretch and fluid shear stress, all induced by the pulsatile blood 
pressure and flow. Endothelial cells bear most of the wall’s shear stress, which is the 
component of frictional forces arising from blood flow and acting parallel to the vessel luminal 
surface3. These cells are very sensitive to such hemodynamic forces, which can be significantly 
altered in regions with disturbed flow. Disturbed flow may occur in the vascular system for a 
number of reasons4. Flow disturbances that naturally occur in certain regions like vessel 
bifurcations or curves, flow alterations generated in arteries through surgical interventions 
such as bypass grafts and stent deployments, flow disturbances as a consequence of disease, 
such as reflux through dysfunctional venous valves, among other causes.  
 
Alternatively, when the compensating artery enlargement is excessive, vessel can become 
patulous and aneurismal. Compensatory hemodynamic forces attempt to maintain arterial 
flow by constantly remodeling the vessel that often sacrifices luminal patency, stress and/or 
geometry. EC exposed to disturbed flow with a low and reciprocating shear stress and EC 
exposed to a laminar flow with a relatively high shear stress show different responses in terms 
of molecular signaling, gene expression, structure and function. For example, endothelial cells 
exposed to disturbed flow are round in shape, with short and randomly distributed actin 
filaments located mainly at the periphery of the cells5, while endothelial cells exposed to 
laminar flow with high shear stress are aligned in the direction of the flow, with parallel actin 
stress fibers in the central regions. EC exposed to disturbed flow also have a higher DNA 
synthesis rate, which enhances proliferation6. Furthermore, disturbed flow increases 
permeability to macromolecules such as albumin or low-density lipoproteins (LDL)7 and 
increases the degree of heterogeneity in gene expression in EC8. This heterogeneity leads to 
an intensification in the levels of certain transcription factors (such as NF-κB or EGF-1)9, cell 
adhesion molecules (like ICAM-1, VCAM-1 or E-selectin10) and other receptors such as the LDL 
receptor11. Flow alterations also regulate platelet aggregation12 and enhancement of 
fibronectin deposition13. The described biological effects of disturbed flow are summarized in 
Table 1. 
 
Many of these effects are directly related to vascular disease and atherosclerosis. The 
formation of atherosclerotic plaques is enhanced in dysfunctional endothelium, where the 
greater permeability to macromolecules such as lipoproteins, the increased expression of 
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adhesion molecules and the enhanced recruitment of monocytes/macrophages in the 
intima - among other effects - favor the progression and development of the disease. 
Therefore, the disturbed and laminar flow patterns induce differential molecular responses in 
endothelial cells, which results in a preferential localization of atherosclerotic lesions. Two 
different combined mechanisms14 explain the differential impact of atherosclerosis and 
thrombosis in arterial bifurcations. On the one hand, non-idealities in flow, “the shear stress 
theory” modify the endothelial response to flow by activating the NF-kB pathway and 
consequently trigger the expression of cell adhesion molecules and other inflammation 
markers. On the other hand, the “mass-transfer theory” states that the cell uptake kinetics of 
lipids and other solutes are concentration- and time-dependent so cells in low shear stress 
recirculating areas such as those in the bifurcations are more prone to uptake solutes such as 







Vasoactivity Vasodilation Vasoconstriction 
Turnover rate Low High 
Macromolecular permeability & LDL Uptake Low High 
DNA synthesis Low High 
Morphology Elongated Polygonal 
Expression of CAMs genes Low High 
Expression of antioxidant genes High Low 
WBC adhesion and platelet genes Inhibition Promotion 
Oxidative stress Low High (sustained) 
SMC activation Low High 
Endothelialization after wound repair Promotion Retardation 
Heterogeneity Low High 
Fibronectin and fibrinogen deposition Low High 
Atherosclerosis and thrombosis Prevention Promotion 
Table 1 - Effects of disturbed flow on EC4 
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1.2 – Atherosclerosis  
Atherosclerosis is a major cause of concern throughout the world leading to millions of deaths 
annually15. Atherosclerosis affects all arterial beds but atherosclerotic lesions form more 
prominently in the vicinity of branch points and areas of curvature, which are more 
vulnerable than unbranched tubular arterial segments4, 16, 17. In these areas, fluid mechanic 
disturbances such as non-uniform laminar flow associated with boundary layer separation, 
recirculation and stagnation produce severe temporal and spatial gradients in wall shear 
stress distributions. These hemodynamic forces are powerful regulators of vascular function 
on a molecular, cellular and tissue level18. 
 
Atherosclerosis is a slow and complex cardiovascular disease that usually affects large and 
medium-sized arteries and is characterized by a thickening of the portion of the arterial vessel 
wall closest to the lumen (Figure 3). Atheromas are not merely filled with lipid, but contain 
cells whose functions critically influence atherogenesis19. Oxidized low density lipoprotein 
(Ox-LDL) activates inflammatory processes at the level of gene transcription by upregulation 
of nuclear factor kappa-b (NF-κB), expression of adhesion molecules (CAMs, such as VCAM-1 
or ICAM-1), and recruitment of monocytes20, 21. As they continue to ingest chemically 
modified lipids and lipoproteins, monocytes become macrophages, which become foam cells 
and initiate fatty streaks. These activated macrophages produce numerous factors that are 
injurious to the endothelium22, 23. The inflammatory process leads to the formation of a 
fibrous plaque which consists of a mass of lipid-engorged monocytes24 covered by a fibrous 
cap and being pushed out into the vessel lumen by smooth muscle cells25 (Figure 4). 
Atheromatous plaques progressively encroach on the lumen to produce luminal narrowing 
and reduce flow to the end-organ. In adverse scenarios, localized plaques may rupture and 
migrate distally to entirely obstruct vascular perfusion and cause severe medical 
complications or even death. 
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Figure 3 - Atherosclerosis evolution26 
 
Figure 4 - Atherosclerotic mechanisms27 
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1.3 – Stents and grafts, the medical treatments against developed atherosclerosis 
Clinical treatment for atherosclerosis has evolved tremendously over many decades and in 
the current generation, percutaneous interventions such as stents and grafts have assumed 
the main stage for many reasons, like their ease of use.  
 
Since Voorhees et al. replaced diseased blood vessels with tubes of synthetic fabric28 in 1952, 
there have been numerous attempts to design a vascular graft that not only matches the 
mechanical properties of the native vasculature, but also promotes cell growth, facilitates 
extracellular matrix production and inhibits thrombogenicity. Approximately 1.4 million US 
patients per year require arterial prostheses29. Synthetic polymer materials, especially 
expanded polytetrafluoroethylene (ePTFE) and polyethylene terephtalate (Dacron), are the 
dominant materials used for applications requiring large-diameter (>6mm) vessels30.  
 
In smaller diameter grafts, however, thrombogenicity and compliance mismatch re-occlude 
the bypassed vessel31, 32, limiting the use of synthetic grafts in applications such as coronary 
artery bypass surgeries (one third of the arterial prosthesis procedures performed each year). 
In these cases, autologous vasculature is used unless precluded by disease, trauma or 
anatomic abnormalities29. The high occlusion rates of synthetic polymer materials has 
motivated further strategies to functionalize the luminal surface of graft materials such as 
coatings, chemical and protein modifications and endothelial cell seeding. Although there 
have been some promising results, synthetic grafts still induce chronic inflammation and 
thrombogenicity33. 
 
More recently, tissue-engineered vascular grafts (TEVG) have emerged to overcome the 
limitations of synthetic grafts. In TEVG, a synthetic or natural biodegradable material acts as a 
scaffold where vascular cells are seeded. The extracellular matrix produced by the cells 
gradually replaces the degrading scaffold. The matrix created, decellularized or not, is then 
implanted to the patient30. This technology provides more favorable hemodynamics, 
mechanical properties and suture force retention than previous synthetic grafts34. Polyglycolic 
acid (PGA) is the preferred scaffold material as it is biocompatible and safely degrades through 
hydrolysis. Biomaterials engineers may adapt the hydrolysis kinetics to the specific patient 
needs by copolymerization with other polymers. Although tissue-engineered vascular grafts 
have yielded promising results; the long culture periods required, the low proliferative 
8 
1 – INTRODUCTION 
capacity of cells isolated from elderly patients and the mechanical immaturity of the vessels 
at the time of in vivo implantation remain major drawbacks.  
 
Stents are metal mesh tubes that are expanded within diseased arteries in order to push the 
obstructive atherosclerotic plaque and return the vessel to a form that re-establishes blood 
flow. Bare metal stents (BMS) were invented and implanted for the first time in the early 
1990’s patients suffering arterial obstructive diseases. The balloon angioplasty and stent 
deployment accomplished an instantaneous recovery of flow in the arteries but the device’s 
presence inside the lumen could lead to hypersensitive reactions that re-occluded (restenosis) 
the arterial vessel and limited its functional lifetime to months35-37. 
 
Adding drugs to coatings on the stents allowed for the direct elution of lesion modifying agents 
from the struts to the vessel. Such modified devices showed promising results by significantly 
reducing the rates of restenosis38. In consequence, different drugs have been added to the 
stents in order to inhibit restenosis pathways, and the first drug-eluting stents (DES) were 
approved by the FDA in 2003. Although the initial results were very encouraging, with a 
reduction from 25.5% to 8.3% in restenosis risk39, the prolonged presence of the drug in the 
arterial wall delayed arterial healing and led to fatal complications such as stent thrombosis 
in 2-3%40, 41 of cases (although some authors consider this an underestimation42), with a 
mortality of 50%43. Impaired re-endothelialization44, excessive fibrin deposition and induction 
of tissue factor expression40 are some of the suggested causes of failure of drug eluting stents. 
To avoid those, practitioners introduced dual anti-platelet therapy for at least 12 months40. 
 
 
Figure 5 - Sirolimus and paclitaxel increase TF transcription40 
Despite technological improvements, restenosis and stent and graft thrombosis continue to 
hamper the success of vascular implants applied to treat the diseased vessel. Implanting 
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vascular devices affects the vessel in different ways. It causes flow disruptions45, which add up 
to the already complex flow regimes present in atherosclerotic regions4, 16, 17. Flow disruptions 
are a parameter to consider while aiming drug delivery to these regions. Device design must 
integrate the influence of flow and drug impact46. In addition, DES and drug eluting balloons 
locally add high doses of anti-proliferative drugs47 to the unhealthy vessel which can impair 
the normal cellular behavior. Sirolimus and paclitaxel were the first drugs employed in DES. 
These have been shown to increase40, 48 (Figure 5) the Tissue Factor (TF) transcription by two 
different pathways. While paclitaxel upregulates the JNK pathway, which directly upregulates 
TF transcription, Sirolimus inhibits mTOR pathway48, which is an inhibitor of the TF 
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1.4 – Tissue factor biology and stent thrombosis 
After percutaneous intervention, balloon angioplasty or stent implantation being the most 
common ones, the device deployed creates an injury36, denudating the vessel from the already 
damaged endothelial monolayer and exposing smooth muscle cells to flow. In the absence of 
anticoagulant therapy, this injury initiates the coagulation cascade (Figure 6). When the vessel 
is injured, collagen and TF are released, starting the intrinsic and extrinsic pathways49. Both 
lead to create a blood clot that covers the injury and allows endothelial cells to proliferate and 
migrate to reconstruct the vessel. While the intrinsic pathway releases the intercellular 
collagen, the extrinsic pathway exposes the TF from the activated endothelium and from the 
sub-endothelial smooth muscle cells and fibroblasts (in case of deep injury) to blood. Both 
pathways, arbitrarily named extrinsic and intrinsic due to previous in vitro work, arrive to the 
common activation of Factor X50. Although both pathways initiate after an injury, the TF 
pathway seems to be the most relevant in vivo51. 
 
Figure 6 - The coagulation cascade52 
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Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood 
through the circulatory system53. Depending on the affected vessel and the degree of 
occlusion, thrombosis can lead to hypoxia, anoxia or even death. As seen in Figure 6, TF 
initiates the extrinsic pathway of the coagulation cascade. TF is a 47 kDa glycoprotein, a 
cytokine receptor class II, present in five pools (cellular and blood) (Figure 7). The protein 
transcription is activated by several cytokines; once transcribed from mRNA, the protein is 
buffered in pools inside the cytoplasm54. This buffer feeds the membrane with surface (active) 
and encrypted (inactive) TF55, 56. The active TF is monomeric, while the encrypted consists of a 
chain of TF monomers. It has been debated whether the formation of a disulfide bond Cys186-
Cys 209 triggers the pro-coagulant activity and protein disulfide isomerase regulates the 
activation55. On the other hand, TF is released into the blood stream in two separate ways, as 
soluble TF (sTF)57, being the external tail of the membrane protein that is released and the 
recently discovered TF-bearing microparticles. No methods have been solidly validated yet to 
quantify TF-bearing microparticles in vitro so they will remain out of the scope of this thesis. 
 
Figure 7 - TF transcription and distribution inside and outside the cells56 
TF exposed on the denuded SMC surface serves as a key precipitant of injury-related local clot 
formation and can lead to stent thrombosis (ST), a potentially lethal event that kills up to half 
of patients. ST risk is particularly amplified in patients with chronic renal failure and end-stage 
renal disease. One-year cardiac mortality after coronary intervention risk can rise up to 6.5-
fold from 1.9% to 15.2% and uremia predisposes to early, late and very late ST58-63. Multiple 
studies in CRF patients have shown increased circulating levels of regulators of thrombosis 
such as soluble TF, activated factor VIII, von Willebrand factor, TF pathway inhibitor, and 
fibrinogen64-67. The effects of uremia on local TF activity in various vascular cell types remain 
however scant. Although uremic serum is known to increase TF expression in EC66, its effect 
on exposed SMC, the key driver of ST, remained undefined. The effect of the uremic serum 
and solutes on SMC TF expression, activity and SMC thrombogenicity will be examined43 since 
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the published data suggested correlation between uremic milieu and hypercoagulability. 
Several studies have shown shear stress dependence on tissue factor expression and other 
coagulation cascade actors68-70, but the results are sparse, and the literature is not clear about 
what the exact effect of flow on tissue factor expression is. Literature is divided in studying TF 
at pre-transcriptional, transcriptional or post-transcription level. This thesis will emphasize on 
cellular TF, which is responsible for coagulation, and soluble TF release, which can be 
internalized by- or signal to EC, always at post-transcriptional level. 
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1.5 – Vessel-like models 
Atherosclerotic plaques preferentially form in certain regions of the vascular tree, such as 
bifurcations and curves, where the disturbed flow enhances a pro-atherosclerotic phenotype 
on endothelial cells. New vascular models must be able to reproduce these flow-dependent 
characteristics, as well as provide new tools to study and characterize the relationship 
between flow patterns and the endothelial function. Several in vitro and ex vivo models have 
been developed to explain partially the molecular mechanisms of atherogenesis, thrombosis 
and restenosis. It is now possible to tailor these models to include patient-specific 
characteristics in the search for personalized solutions. As the vascular system can be 
considered as a closed system, the interaction between flow and the endothelium can be 
studied using in vitro and ex vivo model systems or flow chambers.  
 
In 1986, Badimon et al. designed the first ex vivo chamber71, using de-endothelialized swine 
arteries to prove the relevance of shear rates on platelet deposition. In 2002, Blackman, 
García-Cardeña and Gimbrone, introduced the dynamic flow system (DFS)72 as a culmination 
of decades of research about the effects of flow on endothelial cell biology8, 73. The DFS 
consists of tissue culture wells seeded with functional endothelial cells under controlled 
humidity, temperature and CO2 levels, coupled to a conical device that generates a controlled 
flow over the cultured cells. Also in 2002, Kolandaivelu and Edelman designed and ex vivo 
system to study stent thrombogenicity74, 75; where a rotor provides a customizable inertial 
flow, so the waveforms are totally controlled. This model has been used to study and optimize 
stent designs and enlighten different aspects of stent thrombosis76, among other uses.  
 
EC are not only in direct contact with blood flow but also interact with their underlying cellular 
neighbors (typically, smooth muscle cells). It is then relevant to consider more than one cell 
type in these models. Balcells et al. proved that some flow-dependent endothelial pathways 
are less affected by flow when intact vascular smooth muscle cells are present in the system44. 
These findings, together with other relevant studies, suggest that the optimal strategy to 
create a physiologically relevant in vitro model depends on the cell types considered and the 
in vivo micro and macro environment simulated.  
 
Finally, computational models have gained increasing acceptance as valuable tools to predict 
physical, chemical and biological phenomena in arteries. Computational fluid dynamics (CFD) 
simulations can predict with micrometric precision several physical and biological variables, 
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such as velocity, shear stress and drug distribution profiles. Recent studies47 couple the 
computational results with in vivo experience, but this is only possible when classic mass 
transport equations and molecule-specific uptake kinetics are considered together and with 
accurate input parameters derived and validated from in vivo conditions77. CFD simulations 
are limited by their input validity, but when validated, they offer a platform for repeatable and 
quantifiable assays, across a spectrum of dependent parameters and environmental 
conditions – a feature unachievable with biological and animal testing. 
 
Despite all the efforts made over the last decades, new approaches are needed to obtain more 
precise and informative models, capable of answering biological and clinically relevant 
questions, and focusing on patient-specific characteristics. Considering the uniqueness of 
each patient’s vascular architecture and knowing how each particular geometry determines 
the hemodynamic characteristics and, subsequently, the biological response remain the major 
challenges for present and future vascular models. 
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1.6 – Fluid mechanics in arterial environments 
The conservation of mass, momentum and energy laws provide the basic controls to 
understand fluid behavior in any system. Complex continuum equations derived from the 
conservation laws define the three-dimensional behavior of fluid flows. If one wants to fully 
describe a system, the strategy is dividing the volume to study into n infinitesimal control 
volumes and apply the Navier-Stokes equations to each infinitesimal control volume. 
 
In CFD, the software divides the volume of interest into a finite number of volumes and applies 
Navier-Stokes to each volume. The refinement in size of the mesh of volumes created is critical 
to determine the quality of the solutions. There are very few analytical solutions to the Navier-
Stokes equations and hence assumptions are made to numerically solve them for each control 
volume. In the case of arterial flow, models differ as a function of the assumptions that are 
made. The models can go from the simple laminar, Newtonian fluid flow model to extremely 
complex pseudo-turbulent, shear-rate dependent viscosity models. It is challenging to choose 
the most appropriate model since the comparisons between real and estimated flows are hard 
to obtain empirically. It is important to clarify the limits of refinement of the equations used 
and variables and parameters evaluated to define the scope of study in arterial flow 
mechanics. 
 
The Navier-Stokes equations were discovered after deriving the fundamental conservation 
laws for an infinitesimal control volume (CV) and its control surfaces (CS)78. The conservation 
of mass, where ρ is the fluid density, Vel is the fluid’s velocity, t is time, n�  is a normal vector 




dV + � ρ · Vel������⃗ ·
CS
n� · dA = 0
CV
 
Equation 1 - Conservation of mass 
In the case of steady flow, the partial derivatives versus time of every variable are 0. The 
equation of continuity derives from the conservation of mass law, where u, v and w are the x, 









= ∇Vel������⃗ = 0 
Equation 2 - Equation of continuity 
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After deriving the second law of Newton for the infinitesimal control volume of a fluid one can 
observe that the vector sum of all external forces (F) acting on the control volume is equal to 
the sum of the total rate of change of momentum of mass within the control volume and the 
rate of flux of momentum through the control surface. This relationship is known as the 









Equation 3 - Conservation of momentum 
Finally, the conservation of energy law reveals that the rate of heat (Q) added to the control 
volume minus the rate at which shaft work (Ws) is done is equal to the rate of change of 
energy within the control volume. In the conservation of energy equation, e is the energy 
level, U is the internal energy, p is pressure, g is the gravity and z is height. 
∂
∂t






+ g · z� · Vel������⃗ ·
CS








Equation 4 - Conservation of energy 
It is generally assumed that the state of a given mass of fluid in the control volume in an 
equilibrium state is uniquely specified by two parameters, such as the mass density ρ and the 
pressure p. All other quantities, such as the temperature T in this case, are functions of these 
two state parameters. The conservation laws contain all the unknown variables (velocity, 
pressure, density and temperature) and are enough to determine the system. Derived from 
the conservation of momentum, applying the equation of continuity and assuming newtonian 
fluid (constant viscosity µ) and pressure as only force term, the Navier-Stokes equations read, 
for each direction x, y and z and their respective velocities u, v and w: 
ρ · gx −
∂p
∂x









) = ρ · �∂u
∂t
+ u · ∂u
∂x
+ v · ∂u
∂y
+ w · ∂u
∂z
� 
ρ · gy −
∂p
∂y









) = ρ · (∂v
∂t
+ u · ∂v
∂x
+ v · ∂v
∂y
+ w · ∂v
∂z
) 
ρ · gz −
∂p
∂z









) = ρ · (∂w
∂t
+ u · ∂w
∂x
+ v · ∂w
∂y
+ w · ∂w
∂z
) 
Equation 5 - Navier-Stokes equations 
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Or, in its vector and most commonly cited form: 
ρ · g�⃗ − ∇p + µ · ∇2Vel������⃗ = ρ · (∂Vel
�������⃗
∂t
+ Vel������⃗ · ∇Vel������⃗ ) 
Equation 6 - Navier-Stokes equations in vector form 
The Navier-Stokes system and its derivative equations will be used by CFD software to solve 
the system using the Finite Elements Method (cf. Introduction 1.7). However, Navier-Stokes 
only solves velocity components in flow. If one want to solve mass transfer problems, the 
advection and diffusion equations will be added. This equation is called the material 











Equation 7 - Material derivative of the concentration 
Finally, Equation 8 allows the CFD software to evaluate the mass transfer problems in parallel 
with the velocity, pressure and related mechanic unknowns. In this equation, θ is the 




+ �u · ∇θ�� − ∇(D∇θ) = 0 
Equation 8 - Mass transport scheme used by Tdyn® 
The viscosity of a fluid is crucial to define its velocity profile through a pipe. Considering blood 
vessels perfect cylindrical pipes and deriving the conservation of energy laws for horizontal 
cylindrical pipes with null shaft, the Hagen-Poiseuille law states that the difference of pressure 
along the length L of a vessel follows Equation 9. The adimensional Reynolds number gives 
information on the regime of a flow in a pipe with diameter d. Only flows through pipes with 
Reynolds number higher than 2300 are considered turbulent. 
 
𝑃𝑃1 − 𝑃𝑃2 = 𝑢𝑢 · (8 · 𝐿𝐿 · µ)/(𝜋𝜋 · 𝑟𝑟4) 
Equation 9 - Hagen-Poiseuille law 
Re = ρ · Vel · d/µ 
Equation 10 - Reynolds number
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One obtains a parabolic equation after integrating the Hagen-Poiseuille expression. Blood flow 
velocity generally has a parabolic profile, with maximum speed in the center of the vessel and 
gradually decreasing symmetrically toward the walls (Figure 8). The velocity profile is not only 
a function of space but also a function of time. Arterial pulse is different for each artery, and 
is a complex function of the arterial network upstream and downstream of the studied artery. 
However, healthy arteries close to the aorta should ideally show a perfect peak, similar to a 
narrowed Gaussian distribution. Equation 11 describes parabolic flow through a pipe and the 
Gaussian distribution function for velocity in arteries is show in Equation 12. In those 
equations, x0, y0 and z0 are the coordinates of the center of the inlet, r is the radius of the pipe, 
tpulse is the time of the pulse and σ is the width of the pulse. 
 
Figure 8 - Parabolic velocity profile 
𝑣𝑣 = 𝑣𝑣0 · (1 −
(𝑥𝑥 − 𝑥𝑥0)2 + (𝑦𝑦 − 𝑦𝑦0)2 + (𝑧𝑧 − 𝑧𝑧0)2
𝑟𝑟2
) 
Equation 11 - Parabolic velocity profile 
 





Equation 12 - Gaussian distribution for a pulse
The existence of a stenosis involves, according to the Hagen-Poiseuille law, two main 
hemodynamic effects: an increase of speed at its center point and a decrease in the immediate 
post-stenosis region. The velocity increase is manifested by an increase in flow acceleration 
and a decrease in pressure. Both effects have been correlated with the parietal lesion 
progression. Predicted by Paterson and demonstrated by Burton, the atheroma growth and 
embolization is favored when multiple channels or intraplaque fissures generate a terminal 
pressure gradient higher than the central stream. Burton showed that the maximum risk of 
plaque rupture and secondary thrombus formation is associated with hypertension, since the 
increased pressure gradient promotes intraplaque vibration. Furthermore, and helped by the 
Venturi effect, the increase in acceleration would favor the expansion of the plate79. In the 
segment immediately to the stenosis, velocity near the wall dramatically decreases leading to 
lower shear stress and even recirculating regimes (Figure 9). 
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1.7 – Finite element method 
Systems of differential equations model all the physical phenomena80. These systems are very 
hard or most of the times impossible to solve analytically, so a numerical approach is generally 
the best solution. The finite element method allows for a finite division of the control volume 
into n control volumes that are small enough to be considered infinitesimal. The equations 
defining the fluid properties will be solved for each control volume and integrated along the 
studied geometry. The network of finite elements is called mesh, and it is generally assumed 
that the variables vary in a linear manner over each element81. Given certain initial values and 
boundary conditions, the differential equations governing the system are individually 
calculated for each element and then patched together for the overall geometry following 
certain rules. 
 
The mesh sizing is critical for several reasons. On the one hand, a coarse mesh might lead to 
divergence of the solution since the solver might not be able to patch together the individual 
results for the whole geometry. If convergence of the system were achieved, the result could 
be inaccurate, with low spatial resolution so eventually useless for the engineer. On the other 
hand, over-meshing the geometry would exponentially increase the calculation times for two 
reasons. First, the solver would require more time since it has more control volumes to 
calculate yet more equations to solve. Second, the time increment for each iteration would 
have to be reduced in order to converge a solution. Time increment is the other critical 
parameter in simulations using the finite element method. Again, a compromise between 
accuracy of the solution and resources requirement is necessary. Large increment times will 
result in divergence of the computation but tiny increments will make the computation too 
long, and might at the same time, in certain geometries, affect the stability of the initial steps 
of the calculation, leading again to a loss of convergence. 
 
Two different iterative integration schemes are used to solve any finite element method 
problem. One scheme involves the calculation of the properties of each element and the other 
one involves the congruence of the whole system. The Navier-Stokes system of equations is 
solved for every element using a monolithic implicit solver. Once every element is solved, the 
system of equations with all the particular solutions is solved together using a numerical 
method to solve partial differential equations. The two most common methods to solve these 
systems are Backward-Euler method (1.6.1) and Crank-Nicolson method81 (1.6.2). 
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Equation 14 - Crank-Nicolson method 
The software used to import geometries, mesh them and simulate fluid dynamics and mass 
transfer is the CompassFem v12.1.2 that includes the pre and post-processor GID and the CFD 
module Tdyn® 82. GID is able to create geometries or preferably import them from several file 
formats. It is preferable to import these geometries in format IGES when created with CATIA®. 
GID also allows setting the boundary conditions of the problem in a user-friendly manner. 
Tdyn calculates the solutions and GID reads the solutions file and presents the results in the 
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1.8 – Hypothesis and objectives 
The phenotype of vascular cells is strongly linked to flow characteristics inside blood vessels. 
In parallel, hemodynamics and flow patterns depend upon the geometry of blood vessels and 
biochemical characteristics of blood, which are unique for every patient. This biochemical and 
physical milieu is particularly critical in patients undergoing percutaneous vascular 
interventions.  
 
This thesis hypothesizes that there is a quantifiable correlation between geometry-imposed 
flow disruptions and inflammatory and thrombogenic phenotype in vascular cells. 
Furthermore, this thesis aims to understand some of the mechanisms by which stents, the 
state-of-the-art solution to atherosclerosis, keep hampering vascular health by increasing the 
risk of thrombosis, in particular in stents carrying anti-proliferative drugs and in patients with 
chronic renal failure. To verify these hypothesis, the objectives are: 
 
1. Developing an in silico framework that enables  reproducing any bifurcated artery from 
patient data to: 
a. Simulate blood flow. 
b. Localize and quantify geometry-dependent flow disruptions. 
c. Track soluble tissue factor traffic along the walls of the studied bifurcations. 
d. Manufacture vessel-like polymeric scaffolds that mimic geometries of interest. 
2. Applying the vessel-like polymeric scaffolds to study, in vitro, the correlation between: 
a. Flow disruptions and atherosclerotic progression biomarkers in vascular cells. 
b. Inflammatory milieu and atherosclerotic progression biomarkers in vascular cells. 
c. Flow disruptions and thrombosis biomarkers in vascular cells. 
d. Sirolimus and tissue factor expression in vascular cells. 
e. Uremic serum and solutes and tissue factor expression in smooth muscle cells. 
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A Visual Basic® 2010-based engineered arterial model provides a personalized platform for 
cardiovascular architecture and lesion morphology. Three-dimensional images of patient 
arterial structures are reproduced using CATIA®, a computer aided design (CAD) commercial 
software, and saved as IGS, CAM or STL files, providing the precise coordinates of a given 
arterial bifurcation. CAM image files are used to create Teflon® molds to manufacture 
polydimethylsiloxane (PDMS) scaffolds that mimic the specific vascular bed. The PDMS 
scaffolds are coated with fibronectin as extracellular matrix protein and subsequently, layer-
by-layer assembled with all three cellular components of the arterial wall: fibroblasts, smooth 
muscle cells, and endothelial cells. Using the STL files, a support is 3D printed so the PDMS 
scaffolds may be fit in their tridimensional physiological position and the full architecture of 
the vessel recapitulated. Tdyn®, a commercial computational fluid flow simulator imports the 
IGS files, and performs CFD simulations to predict the map of velocities and shear stresses 
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2.1 – Visual Basic Interface 
The original C code from Kolachalama83 was created to run only simulation using Gambit® 
meshing software. The code was initially adapted to a Visual Basic® 2008 formulary84. It was 
expanded (Figure 10) in order to incorporate the vessel’s curvature both for the simulations 
and for the physical bench model. It also incorporated the option to evaluate the amount of 
recirculation for each region of the bifurcation, to save the current geometry or to load 
previous models. 
 
Figure 10 - Visual Basic 2010 interface 
The program worked for four different applications: CFD, mold design, vessel’s 3D-print and 
support 3D-print. The applications shared the exact same dimensions, obtained through 2D 
angiography, Doppler echography, 3D MRI or 3D Laser Scanning and identified by physicians 
or pathologists as regions of interest for assessment of risk. Two models of bifurcations were 
analyzed, the carotid artery bifurcation and the left main coronary artery. The carotid model 
accounted for the division of the central carotid artery (CCA) into the internal carotid artery 
(ICA) and the external carotid artery (ECA). The coronary model described the left main 
coronary artery (LM) dividing into the left anterior descending artery (LAD) and the left 
circumflex artery (LCX).  
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For the carotid artery, the data from Kolachalama83 were used, but the data obtained at the 
ICC Sant Pau of Barcelona using Eco-Doppler (Figure 11) could also have been applied. For the 
coronary artery, coronary geometries from angiograms of ten different patients at risk of 
cardiovascular disease recruited at the Cardiovascular Section of St. Elizabeth’s Hospital 
(Boston, MA) were retrieved. The protocol was approved by the Institutional Review Board of 
Tufts University Medical Center. Informed consent was obtained and patients’ names were 
deleted previous to the 3D reconstruction. An average of the patients’ data was used to design 
an idealized left coronary bifurcation. In addition, two swine hearts (Figure 12) were scanned 
using a Roland Active Piezo Sensor 3D laser scanner and their coordinates were used to 
establish the curvature of the bifurcation.  
 
Figure 11 - Doppler echography of a 
carotid artery 
 
Figure 12 - Reconstruction of a swine 
heart and outline of the artery of interest 
The interface encoded up to four different macro files for CATIA®, which produced IGES, STL 
and CAM files. Each file was used for a different aspect of reconstruction. The IGES file 
(Figure 13) was the bridge to CFD simulations in Tdyn®. CAM files (Figure 14) drove the 
computer numerical control mechanization of Teflon® molds that would lead to the 
fabrication of PDMS scaffolds. STL files allowed for 3D printing of the selected arterial 
architecture as a flexible polymeric structure (Figure 15) and their curved polycarbonate 










Figure 13 - IGES file for CFD 
 
 
Figure 14 - CAM file for Teflon® machining 
 
 
Figure 15 - STL file for arterial 3D printing 
 
Figure 16 - STL file for support 3D 
printing 
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2.2 – Computational fluid dynamics 
Blood flow simulations were performed in order to study the physical effects of different 
critical parameters of the most relevant arterial bifurcations. The tangential velocity (vTan) 
was the local variable defined to measure the velocity of the fluid flow. The orientation of 
each node of the mesh was determined by the spline (Figure 17) that generated the arterial 
branch. vTan (Figure 18) was calculated as the dot product of its local velocity vector and the 
direction imposed by the spline. This strategy is optimal in curved geometries such as those 
seen in the coronary arteries since it always accounts for local recirculation. CFD calculations 
predicted recirculation downstream of bifurcation and the platform calculated NVV (Equation 
18) to quantify local recirculation for each branch. In further in vitro experiments described in 
section 3.2, NVV was the metric found to better correlate flow recirculations with Ox-LDL 
uptake. Other parameters such as the total volume of recirculation (VolRec) and the 
percentage of volume of recirculation (%VolRec) at the peak of recirculation and their integrals 
along the pulse (Int VolRec, Int %VolRec) correlated worse than NVV. Furthermore, the 
residence time of a particle in a recirculating streamline and the minimal tangential velocity 
on each branch correlated even worse (Figure 19). 
 
By coupling the mass transfer module to the flow dynamics module in Tdyn®, the soluble 
Tissue Factor (sTF) distribution was tracked along the arteries. A stent placed in the vicinity of 
the vertex of each bifurcation separation was simulated. The initial data for sTF concentrations 
was given by the experiment in chapter 4.1.2. The adimensional approach to increase the time 
of experiment is described in chapter 5.9, along with the general equations and particular 
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Figure 17 -  Splines that generated the arterial branch 
 
Figure 18 - Tangential velocity (vTan) calculation scheme 
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Figure 19 - Correlation between Ox-LDL uptake by EC and different recirculation quantifiers 
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2.2.1 – Carotid artery 
The carotid artery is an excellent model of an arterial bifurcation with recirculation areas. The 
CCA bifurcates into the ECA and the ICA, irrigating the brain and all the organs above the neck 
(Figure 20 and Figure 21). Naturally, this bifurcation has certain areas of recirculation that 
increase with age and trigger plaque deposition. The fracture of an unstable plaque can lead 
to an ictus, which is the clotting of a capillary inside the brain, leading to a possible death or 
apoplexy. Also, significant plaque formation within the carotid restricts flow to the brain 
causing symptoms like dizziness, drowsiness, loss of balance. These symptoms occur generally 
in the elderly due to long-term plaque accumulation, but the death rate is significantly lower 
than that attributed to coronary artery disease. 
 
Figure 20 - Carotid bifurcation 
representation85 
 
Figure 21 - Dissected swine carotid 
bifurcation
The author’s blood flow velocity profiles were measured using Doppler echography (Figure 22) 
and adjusted to a pulse following a Gaussian distribution (Figure 23). One can observe a good 
adjustment for the first peak and the omission of the second peak in the model. This second 
peak is a very mild asymptomatic carotid murmur86, and it was decided that only the ideal 
healthy situation would be simulated. 
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Figure 22 - Velocity profiles in the carotid bifurcation using Doppler echography 
 
Figure 23 - Comparison between Doppler echography data and the Gaussian adjustment in 
the CCA 
The inlet velocity profile followed the Gaussian approximation to the real profile: a parabolic 
flow (Equation 16) with a base velocity of 0.1 m/s, a maximal velocity of 0.7 m/s, a Gaussian 
pulse width of 0.05 s and frequency of 60 bpm. The mesh density is shown in Figure 129 and 
the CFD conditions are detailed in Table 4 and Table 5. The recirculation quantification 
methodology is described in chapter 5.9. Recirculation was observed in the two derivative 
branches of the carotid artery (Figure 24 and Figure 25), with severe recirculations in the ICA 
(vTanMIN = -190 mm/s) and mild recirculations in the ECA (vTanMIN = -95 mm/s). The amount 
of recirculation in each branch followed a similar trend (Figure 26). These disrupted flow 
regimes should affect thrombosis and atherosclerosis biomarkers levels. Hence, the sTF 
distribution from a stented region was simulated 30 minutes after stent implantation 
(Figure 27 and Figure 28). The sTF concentration in the vicinity of the arterial wall (stationary 
sTF) in the recirculating regions of the ICA and the ECA increased up to 53% when compared 
to the initial values. Flow elutes the sTF from the injured area and redistributes it along the 
artery. Most of the protein gets washed off downstream the circulatory system, but stationary 
sTF can signal apoptosis87, or contrarily promote proliferation88, enhance inflammation89 and 
in any case becomes coagulant in the presence of phospholipids90. 
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Figure 24 - Recirculation after forward 
pulse in the carotid bifurcation 
 
Figure 25 - Streamlines in the carotid 
bifurcation 
 
Figure 26 - Recirculation quantification in the carotid bifurcation
 
Figure 27 - sTF distribution at time 0 in the 
carotid bifurcation 
 
Figure 28 - sTF distribution after 30 
minutes in the carotid bifurcation 
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2.2.2 – Coronary Arteries 
Coronary arterial bifurcations (Figure 29) are the vessels where fatty plaque genesis is 
accompanied with the highest risk of death; disease on those vessels leads to malfunction of 
the heart. More than 70% of coronary stents are placed within those vessels91, with the left 
coronary artery vascular tree being the one more prone to suffer cardiovascular diseases92. 
The LM bifurcation (Figure 30 and Figure 31) is the bifurcation studied in this thesis. 
 
 
Figure 29 - Coronary arteries representation93 
 
 
Figure 30 - Angiogram of a human LM 
bifurcation 
 
Figure 31 - Dissection of a swine LM 
bifurcation 
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The bifurcation LM-LAD-LCX was simulated in healthy and diseased conditions, flat and with a 
curvature mimicking the underlying pericardium. The mesh density is shown in Figure 130 and 
Figure 131 and the CFD conditions are detailed in Table 6, Table 7, Table 8 and Table 9. The 
inlet velocity profile followed the Gaussian approximation shown in chapter 2.2.1. In the 
healthy scenario, a parabolic inlet (Equation 16) with base velocity of 0.05 m/s, a maximal 
velocity of 0.35 m/s, a pulse width of 0.05 s and frequency of 60 bpm94 were taken as input 
values. The disease case simulated stenosis95 before the LM with a corresponding maximal 
velocity at the inlet of 0.9 m/s. The recirculation quantification methodology is described in 
chapter 5.9. 
 
2.2.2.1 – Flat bifurcation 
The healthy case did not show relevant recirculations. In the diseased case, recirculation was 
observed in the two derivative branches of the coronary artery (Figure 32 and Figure 33), with 
mild recirculations in the LAD (vTanMIN = -66 mm/s) and the LCX (vTanMIN = -62 mm/s). The 
amount of recirculation in each branch followed a similar trend (Figure 34). These mildly 
disrupted flow regimes might affect thrombosis and atherosclerosis biomarkers levels. Hence, 
the sTF distribution from a stented region was simulated 30 minutes after stent implantation 
(Figure 35 and Figure 36). sTF concentration increased an 18% in the proximity of the walls of 
the LAD and the LCX when compared to the initial values. Similarly to the carotid example but 
to a lesser extent, flow drags sTF from the injured area and redistributes it along the artery 
walls and downstream the circulatory system. The stationary sTF in the recirculation zone 
signals vascular injury up to 2 cm away from the injured region.  
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Figure 32 - Recirculation after forward 
pulse in the idealized coronary bifurcation 
 
Figure 33 - Streamlines in the idealized 
coronary bifurcation 
 
Figure 34 - Recirculation quantification in the flat, diseased coronary bifurcation 
 
Figure 35 - sTF distribution at time 0 in the 
idealized coronary bifurcation 
 
Figure 36 - sTF distribution after 30 
minutes in the idealized coronary 
bifurcation
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2.2.2.2 – Curved bifurcation 
The healthy case did not show relevant recirculations. In the diseased case, recirculation was 
observed in the two derivative branches of the coronary artery, but also in the main branch, 
especially very close to the separation area (Figure 37 and Figure 38) with mild recirculations 
in the LAD (vTanMIN = -18 mm/s) and negligible recirculations in the LCX (vTanMIN = -6 mm/s). 
The amount of recirculation in each branch followed a similar trend (Figure 39). These mildly 
disrupted flow regimes might affect thrombosis and atherosclerosis biomarkers levels. The 
sTF distribution was not studied in that particular case. 
 
 
Figure 37 - Recirculation after forward 
pulse in the curved, diseased, coronary 
bifurcation 
 
Figure 38 - Streamlines in the curved, 
diseased, coronary bifurcation
 
Figure 39 - Recirculation quantification in the curved, diseased coronary bifurcation 
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2.3 – Vessel-like scaffolds 
The platform was designed to correlate the flow patterns observed in the CFD simulations 
with expression of cardiovascular disease biomarkers along arterial bifurcations. Hence, an 
automated, reproducible and time-effective method to reproduce physiologically realistic 
geometries had to be developed. The Visual Basic® 2010 interface compiled computer 
numerical control (CNC) files that allowed the manufacture of Teflon® molds to achieve PDMS 
polymerization on their surface. PDMS is a cheap, friendly and biologically inert material that 
polymerizes in a wide range of conditions so it was a potential candidate as polymeric material 
to manufacture the scaffolds. On the other hand, the 3D-Print module generated STL files that 
could directly print the scaffold using photo-polymeric layer-by-layer techniques. Those 
scaffolds would eventually be seeded with vascular cells and be connected to a perfusion 
bioreactor. 
 
2.3.1 – PDMS (Teflon® molds, polyurethane molds and soluble wax core) 
In a first step, two positive Teflon® molds (Figure 40) of the bifurcation were machined using 
a CNC machine Fagor® 8055. Consequently, liquid polyurethane (PU) was poured on the top 
of the two molds to obtain two flexible negative molds after 16 hours curing. The PU molds 
(Figure 42) were assembled to create a cavity identical to the desired bifurcation. A pre-
warmed (700C) optical soluble wax was injected through the cavity and cooled down until 
room temperature to obtain the solid core that would allow generation of the bifurcation 
lumen. To polymerize PDMS from its liquid form, parts A (monomer) and B (curing agent) of 
Dow Corning® Sylgard 164 Silicone Elastomer Kit were mixed in a 10:1 relation and degassed 
using vacuum. The degassed mixture was poured on a negative Teflon® mold that was already 
holding the inner wax cast (Figure 41). The PDMS slowly polymerized following both the core 
and the mold shape. Finally, the solid wax core was dissolved in hot water (800C) for 2 hours. 
After 20 minutes cleaning with a 0.2% sodium dodecyl sulfate solution in distilled water and 
two consecutive rinses with distilled water, the hollow bifurcated scaffold molds (Figure 43) 
were autoclaved at 1200C and 2 bar. In the case of curved coronary bifurcations, the PDMS 
scaffold could be held by the polycarbonate support (Figure 44).  
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Figure 40 - Positive Teflon® 
mold 
 
Figure 41 - Negative Teflon® 
mold with inner cast and 
liquid PDMS 
 
Figure 42 - PU mold and inner 
wax cast 
 
Figure 43 - PDMS scaffold of the carotid 
bifurcation 
 
Figure 44 - PDMS scaffold of the coronary 
bifurcation and its polycarbonate support
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Arterial mimics were constructed from human coronary artery endothelial cells (EC) and/or 
human aortic smooth muscle cells (SMC) under computational guidance built on physiologic 
geometries and flow patterns. Their integrity, viability and functionality was assessed using 
immunofluorescence (IF), scanning electron microscopy (SEM) and Hematoxylin & Elastin 
(H&E) staining. These methods are detailed in chapter 5.5. The constructs were coated with 
100 (coronary) to 150µg/ml (carotid) of fibronectin in phosphate buffer saline (PBS) overnight 
at 40C and washed once to remove loosely adsorbed fibronectin. SMC and EC cultures were 
maintained as detailed in chapter 5.1.3 and sequentially layered as follows. SMC 
(1·106cells/mL) were seeded first on the fibronectin-coated constructs forming a multi-layer. 
After 48h adhesion under axial rotation constructs were filled with an EC suspension 
(1·106cells/mL) and incubated for additional 48h, under identical conditions. Experiments 
were run 48h after this last seeding step. The trilaminate architecture of the vasculature was 
attempted, seeding human aortic adventitial fibroblasts (FB) prior to SMC on the fibronectin-
coated PDMS constructs. Unfortunately, the FB migrated towards the surface up to the EC 
level, detaching from the PDMS surface and peeling off the whole tissue. Individual cell types 
were identified by immunofluorescence (IF). Fibroblasts fluoresced as they were infected with 
a retrovirus containing an eGFP transgene (Figure 45 A), SMC were confirmed via α-SMC-actin 
staining (Figure 45 B) and EC were identified using CD31 marking (Figure 45 C). SEM revealed 
complete cellular coverage along the length and the width of the constructs (Figure 45 D-F) 
and standard histology confirmed the multilayer structure (Figure 45 G). 
 
Figure 45 - FB, SMC and EC within PDMS constructs 
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Functional assays confirmed the biological integrity of each cell type. Fibroblasts functionality 
was resolved by evaluating the cytoglobin levels in mono- and co-culture with SMC and EC96. 
Cytoglobin levels were stable independent of the adjacent seeding of other cells. SMC should 
show a proliferative phenotype when depleted of the overlying endothelium, but remain 
untreated when covered from blood flow by endothelial cells44. Indeed, Ki67-positive SMC 
were 6±1 fold (p<0.05) more abundant when cultured alone (Figure 46 A-C) than those co-
cultured in a trilaminate fashion (Figure 46 D-F). Basal ICAM-1 levels in EC (Figure 47 A-C) rose 
7±1 fold (p<0.05) after stimulation with TNF-α (Figure 47 D-F) as expected when subjected to 
cytokine stimulation18. EC (Figure 48 A) and SMC (Figure 48 B) retained their cytoskeletal 
immunostaining (alpha-tubulin) and alignment with flow.  
 
Figure 46 - Ki-67 expression in SMC alone or in trilaminate culture 
 
Figure 47 - ICAM-1 expression in EC with (right) or without (left) TNF-α 
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Figure 48 - Flow alignment of EC (A) and SMC (B)  
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2.3.2 – Photo-polymeric 3D Print 
The only method able to generate the scaffold in one piece, without burs and with 
homogeneous wall thickness was 3D-Printing the scaffold in a polymer. Moreover, this 
polymer had to be flexible, transparent and more importantly compatible with vascular cells. 
As described in chapter 5.10.2, a 3D Printer Objet Eden 500V printing with Fullcure 930 
Tangoplus polymer was the only possible combination in terms of feasibility and price on one 
hand, and flexibility and transparency of the material on the other. The resultant 3D-printed 
arterial bifurcation can be observed in Figure 49. 
 
 
Figure 49 - 3D-Printed scaffold of the LM-LAD-LCX bifurcation 
The toxicity of the material was initially evaluated by a live/dead assay of cells seeded in tissue 
culture plates and placed in contact with the material for 24 hours. The assay revealed a high 
toxicity of the material if untreated since cell population decreased around 90% (Figure 50). 
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Figure 50 - Toxicity of the untreated 3D material in direct contact with smooth muscle cells 
In order to reduce the toxicity of the material, non-polymerized urethane acrylate and 
methacrylate oligomers (main components of FullCure 930 Tangoplus) were extracted in 
several solvents. Additionally, the material was exposed overnight to UV to help 
polymerization of unreacted monomers. Fibroblasts were exposed for 24 hours to medium 
conditioned with the “clean” material and tested in a live/dead assay. Toluene seemed to 
properly extract the toxic components as cells properly attached to the material as seen in 
Figure 51, despite auto-fluorescence of the polymer. Unfortunately, the process weakened 




Figure 51 - Toluene extraction allowed fibroblasts (DAPI, blue) attachment 
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2.3.3 – Collagen-based 3D Print 
The Swiss company RegenHu® has developed a 3D printer that allows high precision printing 
using collagen-based materials. The printer is installed inside a flow chamber so the printing 
process is already sterile and the material does not require autoclaving. The company was 
able to accurately print a sample of the coronary bifurcation (Figure 52). Further work would 
be required to confirm the biocompatibility and utility of the material. This is a first step to 
implantable arteries based on the platform designed.  
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2.4 – Microparticle tracking 
Simulation results were validated by tracking circulating injected latex microparticles2. The 
trajectory of blue polyethylene microparticles was tracked in the carotid and the flat coronary 
arterial PDMS scaffolds following the methodology described in chapter 5.11. As the 
microparticles had the same density as the fluid (1000 kg/m3), the trajectories followed were 
considered analogue to the simulated fluid’s streamlines. Dextran increased the fluid’s 
viscosity without significantly altering its density up to physiological levels. The experiments 
had a few inherent limitations. Flow was driven by gravity so a continuous flow was imposed 
instead of pulsatile. The maximal velocities in the bifurcations were never reached due to a 
lack of height in the laboratory used. Also, the pump’s vibrations affected the readings and 
interpretation of the data. These limitations may cause divergences between the computer 
simulations and the experimental testing since lower velocities imply smaller recirculation 
areas. A great recirculating pattern was observed in the low shear stress area of the ICA 
branch, the branch with greater recirculations according to the simulations (Figure 24 and 
Figure 26). These data were confirmed experimentally, as observed in Figure 53. As a control, 
particles tracked in the CCA did not experiment any recirculation (Figure 54). 
 
 
Figure 53 - Microparticles recirculating in 
the ICA 
 
Figure 54 - Microparticles in the CCA 
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Intercellular cell adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-
1) expression by EC, the uptake of oxidized low density lipoprotein (Ox-LDL) by EC and the 
adhesion of monocytes to EC were used as biomarkers for atherosclerosis progression. 
Vascular cells were stimulated in several scenarios mimicking vessels that were healthy, 
injured, under inflammatory conditions or exposed to different flow regimes. The main 
objective of these studies was to map thrombosis risk as a function of the cells’ environment.  
 
The cascade of atherogenesis is evaluated along the section. Chapter 3.1 studies the toxicity 
of TNF-α in EC; chapter 3.2, the Ox-LDL uptake; chapter 3.3 and 3.4, the CAMs expression, and 
3.5, the monocyte adhesion in tissue culture plates, straight tubes and bifurcations. In the 
experiments with exposure to flow, it will be discussed which mechanism explains the 
observed results, whether the shear stress mechanism or the mass transfer mechanisms 
discussed in chapter 1.1.  
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3.1. – Toxicity of tumor necrosis factor α in EC 
The inflammatory cytokine tumor necrosis factor α (TNF-α) triggerss the inflammatory 
response through activation of the nuclear factor kappa-light-chain-enhancer of activated B 
cells (nf-κB) pathway but also kills vascular cells by triggering apoptosis. The cell survival is a 
function of exposure time to the cytokine and concentration of the cytokine. EC were cultured 
in TCP and exposed during 6, 12 or 24 hours to 5, 15 or 25 ng/mL of TNF-α. Cells exposed to 0 
ng/mL of TNF-α during 24 hours served as negative control. After exposure, viability was 
evaluated using a live/dead assay. Results are presented as percentage of viable cells, which 
is a function of exposure time and TNF-α concentration (Figure 55). From this experiment on, 
the concentration used for every experiment requiring inflammatory activation was 3 ng/mL 
of TNF-α, concentration able to activate VCAM-1 expression (Figure 66) and not lethal to EC. 
 
Figure 55 - TNF-α toxicity in EC 
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3.2 – Ox-LDL uptake 
Ox-LDL is a crucial player in the progression of 
atherosclerosis (see chapter 1.2). A commercial 
derivate of Ox-LDL, Dil-Ox-LDL was used to estimate 
Ox-LDL uptake by activated EC. 1,1'-Dioctadecyl-
3,3,3',3'-Tetramethylindocarbocyanine Perchlorate 
(Dil) is a fluorescent marker that emits at a 
wavelength of 580 nm and its presence in the samples 
was directly correlated to Ox-LDL absorption. This 
absorption was evaluated by immunofluorescence. 
The dose-response curve of Ox-LDL by EC was 
obtained. Cells grown on multiple well plates were 
exposed to 0, 5, 7.5 and 10 µg/mL for 48 hours, all 
within physiological values. Ox-LDL absorption was 
significant after the threshold of 7.5 µg/mL (Figure 56 
and Figure 57). At 10 µg/mL (Figure 56), EC started to 
lose confluence as they detached and agglomerated. 
Interestingly, the Ox-LDL uptake was not affected by 
the presence of TNF-α (Figure 58). From these 
experiments on, the concentration of Ox-LDL was set 
to 7.5 µg/mL in EGM-2, without TNF-α activation. 
 
Figure 56 - Evolution of EC morphology 
as a function of Ox-LDL concentration 
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Figure 57 - Ox-LDL uptake by EC as a function 
of Ox-LDL concentration 
 
Figure 58 - Ox-LDL uptake by EC in the 
presence or absence of TNF-α
An initial test was run (Figure 59) to determine the homogeneity of the uptake along a tube. 
Untreated EC were exposed to arterial flow or static control for 24 hours. The tube was cut in 
four 2 cm-long sections (A, B, C, D) and the Ox-LDL content was evaluated for each section. 
The absorption was homogeneous along the tube. A second set of experiments was run in 
straight tubes seeded with EC, exposed to 24 hours of arterial flow, oscillatory flow and static 
control. As seen in Figure 60, oxidized LDL uptake rose 2.3-fold when EC were exposed to 
oscillatory flow and under static conditions. One may hypothesize that the mass transfer 
component is predominant since the oscillatory case and the static case have both null net 
flow. 
 
Figure 59 - Ox-LDL uptake by EC along a 
tube 
 
Figure 60 - Ox-LDL uptake by EC exposed 
to arterial flow, oscillatory flow and static 
control 
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In the bifurcated models, the Ox-LDL uptake increased linearly with the intensity of 
recirculations, up to 3-fold higher than upstream of the bifurcation divider in the internal 
carotid artery. As seen in Figure 61, the uptake perfectly correlated with the amount of 
recirculation in each branch of the carotid bifurcation. In Figure 62, one can observe that the 
increase in Ox-LDL is slightly lower than the increase in recirculations. Nevertheless, the Ox-
LDL uptake still rose about 50% in the LCX and LAD. 
 
 
Figure 61 - Ox-LDL uptake by activated EC 
in the carotid bifurcation model 
 
Figure 62 - Ox-LDL uptake by activated EC 
in the coronary bifurcation model 
 
Figure 63 - Images of the Ox-LDL uptake by activated EC in each branch of the carotid 
bifurcation model
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3.3 – ICAM-1 expression 
ICAM-1 is a marker of activation of the intercellular NF-κB pathway, and its expression is 
triggered by inflammatory stimuli. There is a disparity in the literature regarding differential 
expression of ICAM-1 as a function of flow. While some authors determine that ICAM-1 levels 
are homogeneously increased in diseased vasculature in the presence of flow18, 97, others 
affirm that ICAM-1 expression is stimulated by oscillatory shear stress98, 99. Endothelial cells 
were stimulated overnight with 3ng/mL of TNF-α and/or 7.5 µg/mL of Ox-LDL, and ICAM-1 
levels measured by immunofluorescence. As seen in Figure 64, while the addition of Ox-LDL 
did not affect the ICAM-1 levels, exposure to 3 ng/mL of TNF-α was enough to increase ICAM-
1 expression 2.5-fold. In EC and SMC seeded on straight tubes exposed to 24 hours of arterial 
flow, oscillatory flow and static control, ICAM-1 was almost undetectable without TNF-α 
activation. In Figure 65, the vascular cells were activated with 3ng/mL but the relative levels 
remained very similar both for EC and SMC. These results and the discrepancies observed in 
the literature prompted to discard ICAM-1 as biomarker of flow disruptions. 
 
 
Figure 64 - ICAM-1 expression as a 
function of time and presence of TNF-α 
and Ox-LDL 
 
Figure 65 - ICAM-1 expression in EC and 
SMC exposed to arterial flow, oscillatory 
flow and static controls 
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3.4 – VCAM-1 expression 
VCAM-1 is the protein that signals for monocytes recruitment and LDL uptake. Its expression 
reveals activation of the NF-κB pathway and is triggered by inflammatory stimuli. To confirm 
the data from the literature, endothelial cells were exposed for 12 hours to 3ng/mL of TNF-α. 
VCAM-1 expression was evaluated by western blot. As seen in Figure 66, the addition of TNF-
α increased VCAM-1 expression 10-fold. 
 
Figure 66 - VCAM-1 expression as a function of presence or absence of TNF-α 
After confirming the increase in VCAM-1 expression under inflammatory conditions, EC 
seeded on straight tubes were exposed for 24 hours to arterial flow, oscillatory flow or static 
control, with and without TNF-α activation. As seen in Figure 67, EC exposed for 24 hours to 
low shear oscillatory flow (OF) increased a significant 60% their expression of VCAM-1 versus 
those exposed to coronary artery-like flow (AF). Arterial flow, unlike oscillatory flow offers 
seemingly protective effects on EC. Figure 68 shows how the difference in expression of 
VCAM-1 was muted when EC were activated by TNF-α. The same observations were made in 
the carotid (Figure 69) and coronary bifurcation (Figure 70) models, where VCAM-1 expression 
in activated EC remained not flow-sensitive. Thus, not only can disrupted flow exacerbate 
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Figure 67 - VCAM-1 expression in 
untreated EC 
 
Figure 68 - VCAM-1 expression in 
activated EC 
 
Figure 69 - VCAM-1 expression in activated 
EC in the carotid bifurcation model 
 
Figure 70 - VCAM-1 expression in activated 
EC in the coronary bifurcation model 
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3.5 – Monocyte adhesion to EC 
Monocytes recruited by EC into the sub-
endothelial matrix play a key role in the 
progression of atherosclerotic plaques. 
Blood from different healthy donors was 
used to evaluate monocyte adhesion. 
Recruitment was evaluated after fixing the 
samples and immunostaining them against 
α-tubulin and using DAPI to reveal nuclei. 
DAPI and tubulin signal intensities were 
significantly higher in monocytes than in 
EC, while monocyte size was significantly 
smaller than EC’s size (1:100). These 
parameters were used to isolate 
monocytes from the EC matrix and count 
them using the image analysis software 
ImageJ. In preliminary assays, adhesion of 
monocytes was tested on confluent EC on 
TCP to estimate the amount of monocytes 
needed to pursue the perfusion bioreactor 
experiments. The isolated monocytes (see 
chapter 5.4) were incubated for 2 hours at 
37ºC on activated EC in monocyte/EC 
ratios 0, 0.25, 0.5 and 1. As seen in 
Figure 71, the optimal ratio for 
quantification and signal to noise ratio was 
1 monocyte/EC, and this was the ratio used 
in further experiments. 
 
Figure 71 - Monocyte adhesion to EC on 
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The adhesion was analyzed in straight tubes seeded with EC exposed to 24 hours of arterial 
flow, oscillatory flow or static control and activated with TNF-α. After exposure to the different 
flow regimes, constructs were extracted from the flow loop and rotated at 37ºC and 5%CO2 
with previously isolated monocytes. This technique allows only studying the shear stress 
mechanism. This technique was used because monocytes died when pulsed with a peristaltic 
pump. As seen in Figure 72, in the presence of null net flow (oscillatory and static scenarios), 
the monocyte recruitment by activated EC doubled when compared to the arterial flow 
recruitment. 
 
Figure 72 - Monocyte adhesion to activated EC exposed to arterial flow, oscillatory flow or 
static controls 
In the bifurcated models, the monocyte attachment increased linearly with the intensity of 
recirculations, up to 2-fold higher than upstream of the bifurcation divider in the internal 
carotid artery. As seen in Figure 73 and Figure 74, there was a fair correlation between 
monocyte adhesion and with the amount of recirculation in each branch of the carotid and 
the coronary bifurcation. In both figures one can observe that the difference between 
adhesion levels between the upstream branches (LM and CCA) and the recirculating branches 
is lower than expected from values predicted by NVV. Nevertheless, the increases observed 
in every recirculation branch (50 to 100% increase) suggest that disrupted flow regimes 
differentially activate endothelial cells and hence monocyte recruitment. The mass transfer 
mechanism, which is omitted due to the procedure used, cannot be neglected due to the size 
and weight of monocytes. It is predictable that the model underestimates the total 
recruitment and that the actual in vivo values are much higher than those observed in vitro. 
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Figure 73 - Monocyte adhesion to 
activated EC in the carotid bifurcation 
model 
 
Figure 74 - Monocyte adhesion to 
activated EC in the coronary bifurcation 
model 
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Tissue factor (TF) expression and activity in EC and SMC, thrombogenicity and re-
endothelialization after injury were used as biomarkers for thrombosis. Vascular cells were 
stimulated in several scenarios mimicking vessels that were healthy, injured, under 
inflammatory conditions, stented, under anti-proliferative drug effects, exposed to different 
flow regimes and exposed to uremic solutes or serum. The main objective of this section of 
the thesis was to map thrombosis risk as a function of the cells’ environment.  
 
Chapter 4.1 studies cardiovascular disease biochemical and physical milieu, analyzing 
characteristics such as injury, flow and anti-proliferative drugs and chapter 4.2 studies uremic 
biochemical milieu. In chapters 4.1.1 and 4.2.1, whole cell TF expression is examined. 
Although, as seen in chapter 1.4, only monomeric membrane TF triggers coagulation by 
activating Factor VII and subsequently activating Factor X, the whole cell TF is a good indicator 
of thrombotic risk. In chapter 4.1.2, the intra- and inter-cellular trafficking of TF and sTF is 
evaluated. As seen in chapter 1.4, TF is not only expressed in the cellular membrane, but is 
also secreted to the blood stream as soluble tissue factor (sTF). Soluble TF released from an 
injured region, a given drug eluted from a drug eluting stent, and other inflammatory 
cytokines remain in the recirculation areas instead of being drained downstream and diluted 
systemically in the circulatory system. These solutes’ trafficking depend upon the geometry of 
the stented artery and upon the stent positioning along the artery. The released solutes from 
the injured stented area are expected to increase TF levels downstream of the stented regions, 
especially in recirculating areas. In chapters 4.1.3 and 4.2.2, TF activity is studied, using two 
different approaches. One method evaluates the amount of activated Factor X and the other 
method evaluates total thrombogenicity of the sample. The Factor X assay does not 
necessarily correlate with the final thrombogenicity in vivo because other molecules like TFPI 
can disrupt the coagulation cascade. The thrombogenicity assay cannot fully correlate 
thrombus with TF activity since other biomolecules such as collagen can lead to blood 
coagulation. Nevertheless, the combination of both methods leads to reliable results in terms 
of correlation between TF content and activity, and vessel thrombogenicity. TF ability to 
initiate coagulation can be suppressed when applying anti-TF antibodies to the samples prior 
to the thrombogenicity assay. Chapter 4.1.4 will study re-endothelialization as a function of 
flow and correlate it to thrombogenicity in stents.  
-  
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4.1. – Cardiovascular disease related risk factors 
4.1.1 – TF expression 
TF expression in basal conditions was evaluated in SMC and EC by immunofluorescence 
(Figure 76). TF expression in EC was below detectable levels but SMC expressed TF 
constitutively. EC and SMC exposed for 24 hours to 3 ng/mL of TNF-α and/or injured with cell 
scrappers to map TF expression as a function of cell type, TNF-α presence and proximity to 
the injury (Figure 77). TF intensity (green) in SMC did not react to TNF-α presence but 
increased in the edge (50-100µm away) of the injury. 
 
Figure 76 - Basal TF expression (red) in EC 
(top) and SMC (bottom) 
 
Figure 77 - SMC (left) and EC (right) TF (green) in 
presence of injury (I, red mark) and TNF-α (T) 
 
Mono-cultures of SMC and co-cultures of SMC underlying EC were cultured and exposed for 
24 hours to 0 or 10 nM sirolimus and/or injured with cell scrappers to map TF expression as a 
function of cell type, sirolimus presence and proximity to the injury. In Figure 78 and Figure 79, 
TF (red) and PECAM-1 (green) were labelled. Relative fluorescence was analyzed using ImageJ. 
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In both experiments (SMC alone and SMC/EC co-culture), cells on the edge of the injury 
showed higher levels of surface TF than intact controls. The TF expression in co-cultures and 
mono-cultures exposed to sirolimus increased to a similar extent than cells injured. In the case 
of double stimulation (injury + sirolimus), sirolimus synergistically increased TF expression in 
SMC healing the injury. Samples were not permeabilized during the immunostaining 
procedure. This way, the diffusion of the antibody anti-TF through the endothelial shield 
mimicked the molecules binding to TF present in the blood torrent (Factor VII and Factor X). 
TF expression evaluated by immunofluorescence was indeed tuned down by the presence of 
EC shielding the SMC. 
 
Figure 78 - TF expression (red) in SMC 
healing an injury 
 
Figure 79 - TF expression (red) in SMC 
shielded by EC (CD31, green)  
 
Figure 80 - TF expression as a function of presence or absence of injury (I) and sirolimus (S) in 
EC overlying SMC and SMC 
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The effect of 24 hours exposure to arterial flow (AF) on TF expression was evaluated in SMC, 
EC and SMC underlying EC. TF was immunostained and the TF concentration evaluated using 
ImageJ on the confocal microscope images (Figure 81). TF levels in EC were below the 
detection threshold. TF expression was 1.5 to 2-fold lower in SMC exposed to AF versus the 
static control (Figure 82). This result was confirmed in the co-cultures, where, as previously 
seen, EC shielded SMC. The fact that null shear cells expressed twice the amount of TF suggests 
that in areas with low shear flow disruptions, TF expression would be higher than in arterial 
flow regimes. 
 
Figure 81 - Images of TF expression (red) in SMC alone (left) or underlying (right) EC (CD31, 
green) when exposed to arterial flow (AF) or static control (STA) 
 
Figure 82 - TF expression in SMC and EC overlying SMC exposed to arterial flow (AF) or static 
control (STA) 
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TF expression was evaluated in mono-cultures of activated EC (before intervention) and in 
untreated SMC (after intervention) after exposure to 24 hours of arterial flow, low shear 
oscillatory flow and static controls. TF expression by SMC was evaluated using 
immunofluorescence and TF expression by EC was measured using western blot. Preliminary 
experiments suggested activation of EC with 3 ng/mL of TNF-α to detect TF in EC using western 
blot. AF decreased SMC’s TF expression compared to static conditions (1.75-fold decrease). 
More interestingly, oscillatory flow enhanced TF levels exceeding the static control, 2.5-fold 
higher than the AF results (Figure 83 and Figure 85). Oscillatory flow is a model of flow 
disruptions, and literature100 has proved that flow regime around stent struts is oscillatory. 
The TF expression data on oscillatory flow is very interesting since it implies that oscillatory 
flow around the stent strut increases the TF expression in SMC and hence its thrombogenicity. 
In activated EC, the oscillatory flow caused a tremendous 4.5-fold increase in TF expression 
but the static control remained similar to the arterial levels (Figure 84 and Figure 86). These 
data suggest that only the combination of strict oscillatory flow combined with inflammatory 
conditions increases thrombogenicity in intact EC. It also suggests that thrombogenicity in the 
stent strut surroundings can be due not only to flow-exposed SMC, but also to injured EC in 
inflamed regions exposed to oscillatory flow regimes. 
 
 
Figure 83 - TF expression in untreated SMC 
exposed to arterial flow, oscillatory flow 
or static controls 
 
Figure 84 - TF expression in activated EC 
exposed to arterial flow, oscillatory flow 
or static controls 
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Figure 85 - TF expression in untreated SMC exposed to arterial flow, oscillatory flow or static 
controls, evaluated by immunofluorescence 
 
Figure 86 - TF expression in activated EC exposed to arterial flow, oscillatory flow or static 
controls evaluated by western blot 
The deployment of a stent in an artery injury in the vessel and flow disruptions around the 
stent strut. These two elements combined with the anti-proliferative drugs coating the drug 
eluting stents may enhance TF expression. Experiments were performed in order to study the 
effect of stenting in SMC TF expression. Effects of injury, drug and flow disruptions were 
examined in parallel. In an initial approach to understand TF distribution downstream of the 
stented region, straight tubes were sectioned following the scheme in Figure 87 The areas 
defined were “Stent”, “Proximal”, “Medial” and “Distal”, where “Stent” corresponded to the 
stented region, “Proximal” extended from 0 to 5 mm after the stent, “Medial” from 5 to 10 
mm and “Distal” from 10 to 15 mm. 
 
Figure 87 - Regions distribution 
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Straight constructs were seeded with SMC, stented with NIR Stents (see chapter 5.1.5) and 
exposed to arterial flow or static controls (Figure 88). There were no significant differences 
between the proximal, medial and distal zones in the static controls as expected in the 
absence of flow disruptions. The stented area, however, showed higher TF expression due to 
the injury caused by the stent. In SMC exposed to AF, the stented area showed a significant 2-
fold difference with the medial and distal area. More interestingly, the proximal and stented 
area presented very similar levels of TF. Two mechanisms potentially took place and resulted 
in the measured increased TF within the proximal region. On the one hand, flow disruptions 
caused by the stent should increase TF levels in the vicinity of the stent. On the other hand, 
the soluble TF released in the stented area might be increasing the TF content in the SMC in 
the proximal area similarly to what has been published with other proteins100. 
 
 
Figure 88 - TF expression in SMC exposed to arterial flow or static controls after stenting 
 
Cordis® bare metal stents and sirolimus eluting stents were expanded in straight constructs 
seeded with SMC underlying EC. The experiment compared the effects of balloon injury alone, 
deployment of a bare metal stent and deployment of a sirolimus eluting stent on TF expression 
after 24 hours of arterial flow or its static control. Results were evaluated by 
immunofluorescence. Figure 89 shows the matrix of results of this experiment. 
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Figure 89 - TF expression in SMC with overlying EC, exposed to arterial flow (AF) or static 
control (STA) and left intact (INT) or injured with a balloon (BIN),a bare metal stent (BMS) or 
a sirolimus eluting stent (SES) 
A 1.75 to 2.5-fold average decrease in TF values was observed again for cells under arterial 
flow versus those under static conditions. No significant differences were observed between 
TF expression in cells injured with a balloon and TF expression in cells injured with a bare metal 
stent. This suggests that the overexpression of TF due to the injury during stent implantation 
is mainly caused by the balloon protruding in the inter-strut region In terms of TF upregulation, 
doing an angioplasty or deploying a stent was equivalent. Both for flow and static conditions, 
cells injured with drug eluting stents expressed 1.2 to 1.5-fold more TF than those injured with 
balloon or bare metal stents, in accordance with published data101. More interestingly, and 
particularly in the flow experiments, sirolimus and sTF eluted to the cells downstream the 
stent, causing an increase of TF expression in the medial and distal areas to the stent, 
especially in the sirolimus eluting stents. 
 
To mimic the diseased vessel before and after stenting or angioplasty, TF expression was 
evaluated in mono-cultures of activated EC (before intervention) and in untreated SMC (after 
intervention) after exposure to 24 hours of arterial-like flow in the bifurcated models. TF 
expression in SMC had direct correlation with the amount of recirculation in each branch of 
the studied bifurcations (Figure 90 and Figure 91). It rose up to 2-fold in the ICA but only a 
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35% in the ECA when compared to the CCA values. In the coronary bifurcation, the increase 
ranged between 35% and 50% for LAD and LCX vs. LM. Very surprisingly, in apparent 
discordance with the observations from the simplified model, TF expression in activated EC 
decreased about 50% in the ICA and ECA compared to the CCA (Figure 92). In the coronary 
bifurcation, the TF expression did not significantly differ among cases (Figure 93). Globally, 
high recirculation levels downregulated TF in activated EC and mild recirculation did not affect 
the values. These results suggest a complex interaction between the different flow fields 
within the bifurcated region.  The complete mechanism remains to be fully understood. 
 
 
Figure 90 - TF expression in untreated SMC 
in the carotid bifurcation model 
 
Figure 91 - TF expression untreated SMC in 
the coronary bifurcation model 
 
Figure 92 - TF expression in activated EC in 
the carotid bifurcation model 
 
Figure 93 - TF expression in activated EC in 
the coronary bifurcation model 
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4.1.2 – TF trafficking 
An experiment was performed to evaluate sTF release in vascular cells under conditions 
simulating a stented region. sTF release was evaluated in EC, SMC and EC overlying SMC 
cultured on TCP and exposed for 48 hours to 0 or 10 nM sirolimus and/or injured with cell 
scrappers. Preliminary results (Figure 98) indicated that the activity of TF was higher after 48 
hours of exposure to injury and sirolimus. After exposure, supernatant media was collected 
and sTF content was evaluated by ELISA. The values obtained were used to run sTF distribution 
simulations (Figure 27, Figure 28, Figure 35 and Figure 36) and to define critical regions in 
terms of sTF deposition. As seen in Figure 94, sTF release by EC mono-cultures was near the 
detectability threshold and sTF release by mono-cultured SMC was independent of the stimuli. 
In co-culture, sTF release by injured cells was higher than sTF released by sirolimus stimulated 
cells and higher than the intact control. The combination of sirolimus and injury slightly 
increased the sTF release values from only injured cells. 
 
Figure 94 - sTF release in EC, SMC and SMC underlying EC stimulated by injury (I) and/or 
sirolimus (S) 
In a second set of experiments, co-cultures of SMC and EC in TCP were stimulated in conditions 
mimicking a stented environment. Cells were exposed for 48 hours to 0 or 10 nM sirolimus 
and/or injured with cell scrappers. After the exposure, the supernatant media was collected 
and exposed for 48 hours to intact, untreated monocultures of EC and SMC and co-cultures of 
SMC and EC. This step simulates the exposure of healthy vascular cells downstream a stented 
vessel to the inflammatory cytokines released by the process of stenting. Cells were exposed 
to the conditioned medium for 24 hours and TF values were evaluated by western blot of the 
whole cell lysate (Figure 95). 
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Figure 95 - TF expression by untreated EC, SMC and SMC/EC exposed to conditioned medium 
from SMC/EC stimulated by injury (I) and/or sirolimus (S) 
Total TF in EC, SMC and co-cultures of SMC underlying EC was higher when cells were exposed 
to conditioned medium from SMC/EC stimulated by injury and sirolimus. Also, conditioned 
medium from sirolimus-only stimulated SMC/EC did not seem to alter the basal TF levels in 
any of the three combinations of exposed cells. Although TF expression in EC mono-cultures 
was generally below detectability limits, EC seemed sensitive to injury and injury plus sirolimus 
conditioned media. As a final observation, TF expression in SMC/EC co-cultures was 
approximately half the expression in SMC mono-cultures. These results are in accordance with 
the 1:1 ratio at which SMC and EC were seeded in the co-culture and confirm that, also in co-
culture, SMC are the main source of TF. This is not an affirmation but an assumption because 
the methodology used (whole cell lysate) cannot separately analyze EC and SMC contribution 
to TF expression. One can solidly conclude in any case that injury and injury plus sirolimus 
conditioned media promote TF increase in quiescent SMC/EC co-cultures and that this is 
relevant to stent design and placement. 
A series of mechanisms can be proposed to explain the results previously described. Sirolimus 
might be promoting TF internalization and preventing downstream expression by not allowing 
release to the medium. This might be achieved by inhibiting the intracellular TF trafficking 
pathway. One could also think that the EC shielding in SMC/EC co-cultures affects sirolimus-
SMC interaction and/or prevents sTF release from SMC to the medium. EC may however still 
be able to promote TF activation to underlying SMC through paracrine signaling, even with 
efficient shielding from molecules promoting TF in the conditioned medium. Also, if EC 
shielding was not efficient, TF promoters could diffuse through the endothelial monolayer and 
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induce TF expression to underlying SMC. Finally, another less complicated hypothesis states 
that sirolimus degrades and loses efficiency along the 96 hours that the experiment lasts. A 
series of experiments can be proposed to confirm the hypothesis previously stated. The 
intracellular trafficking of TF and compartmentalization could be studied to understand 
whether sirolimus enhances TF localization in a certain cellular pool54. Ultracentrifugation 
(Figure 96) confirmed that the cellular membrane allocated most TF, but the cytoplasm and 
the nucleus contents were not negligible. The effect of sirolimus in TF compartmentalization 
has not been elucidated yet. Finally, the biochemical mechanistic of sTF in cells downstream 
the stented region should be evaluated to determine whether sTF gets internalized by 
untreated cells or promotes TF expression. The approach would be to genetically modify the 
released sTF to make it fluorescent and determine its presence in downstream cells. In 
parallel, one should tag TF produced by downstream cells in order to fully differentiate sTF 
uptake from TF expression engagement. 
 
Figure 96 - TF distribution in the cytoplasm (CYT), nucleus (NUC) or membrane (MEM) in SMC 
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4.1.3 – TF activity 
As seen in chapter 1.4, TF is able to bind to Factor VII and trigger coagulation only when it’s 
active. Only membrane TF in monomeric state is able to initiate the coagulation cascade and 
is hence “active TF”. A logical approach would be quantifying monomeric TF in the membrane 
fraction of whole cell lysate. To do so, whole cell lysate may be lysed using non-reducing lysis 
buffers to run native western blot and protect the original protein polymerization. 
Unfortunately, the ultracentrifugation technique required reducing reagents and yet native 
western blot and ultracentrifugation were not compatible techniques. The method to quantify 
only monomeric (active) TF was assayed in confluent SMC cultured on tissue culture plates. 
The method worked but was not applicable to the vessel-like constructs due to the lower 
cellular concentration present in constructs. Figure 97 shows an example of a native gel where 
multiple TF polymers can be observed. 
 
Figure 97 - TF expression by untreated SMC in a native gel 
TF activity may be measured by other means. As active TF activates Factor VII and Factor X is 
activated by Factor VIIa, a measure of Factor Xa concentration would correlate with TF activity. 
To measure sTF activity, a co-culture of SMC and EC on TCP was injured with cell scrappers 
and exposed to 10 nM sirolimus for 48 hours (Figure 98). Then, in a consecutive experiment, 
untreated SMC were exposed to the collected conditioned medium. After 24 hours, activity of 
sTF present in the medium was measured (Figure 99). In both experiments concentration of 
Factor Xa in the medium was measured using an activity assay. In the first experiment, the 
released sTF activity showed a first 2-fold peak after 2 hours, decreased to basal levels, but 
increased again between 24 and 48 hours to reach an apparent 4-fold plateau. Given the acute 
nature of TF as trigger of the coagulation cascade after injury, one may hypothesize that the 
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peak observed after 2 hours is an acute response to injury and the second peak responds to 
the action of sirolimus. In the second experiment, the sTF activity started peaking after 2 
hours, and reached a 2-fold plateau after 4 hours. In this case, sTF is an indistinguishable sum 
of the original sTF present the original conditioned medium and the sTF released by SMC. In 
any case, it is always higher than the one observed in Figure 98, indicating extra release by 
SMC after sensing condition medium. This result is relevant in terms of stenting. It indicates 
that vascular cells downstream of a sirolimus-stented region sense injury and drug presence 
upstream and reacts by increasing the activity of soluble TF. 
 
 
Figure 98 - sTF activity measured in medium 
released by injured SMC/EC exposed to 10 
nM of sirolimus 
 
Figure 99 - sTF activity released by SMC 
exposed to conditioned medium from injured 
SMC/EC stimulated by 10 nM sirolimus for 
48 hours
Another strategy to evaluate TF activity is measuring cellular thrombogenicity. This way, one 
can correlate increase in TF expression with increase in TF activity without measuring 
monomeric membrane (active) TF. The flow loop assay described in chapter 5.3 was used to 
determine thrombogenicity in straight cell-seeded constructs. The prototype needed to be 
much further developed to assess thrombogenicity in the bifurcated models and hence no 
experiments were run with bifurcated models. The method had never been used before to 
estimate TF activity in vascular cells. A slight modification of the method was also applied 
(Figure 100): first, the heme concentration was linear with blood concentration in the lysate 
so it could be directly correlated with the amount of thrombus. Second and more interestingly, 
the direct measure of the absorbance of the sample at 405nm correlated with the measured 
heme concentration. Thanks to this correlation, a heme quantification assay was not needed 
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and hemoglobin concentration could be estimated by directly measuring the absorbance of 
the lysed sample. A preliminary experiment was run to adjust the experimental conditions for 
cell-seeded constructs (Figure 101). Four straight tube types were tested. The first set was 
empty, the second had been treated with fibronectin, the third had been seeded with SMC, 
and the fourth was seeded with EC. The experiment confirmed that SMC denuded from EC are 
much more thrombogenic than EC. Also, untreated or fibronectin-coated silicon rubber tubes 
were not thrombogenic. 
 
 
Figure 100 - Hemoglobin concentration in blood 
measured through heme assay or with direct 
absorbance 
 
Figure 101 - Thrombogenicity in straight 
tubes 
A matrix of experiments was performed to understand how flow and stent injury interact in 
stent thrombosis. Straight tubes seeded with EC, SMC or SMC underlying EC were stented with 
NIR stents or left intact and exposed to arterial flow, oscillatory flow and static controls. 
Figure 102 and Figure 103 summarize the results. Intact EC, SMC and EC/SMC constructs were 
always more thrombogenic when exposed to oscillatory flow. In the static controls, EC and 
EC/SMC were as little thrombogenic as arterial flow, but not SMC alone, that were as 
thrombogenic as the oscillatory case. These results are in accordance with those depicted in 
Figure 83 and Figure 84, and confirm TF as a good biomarker for thrombosis in this 
experimental setup. Furthermore, the EC/SMC construct, when intact, behaves exactly like an 
EC monoculture. When cells were stented and exposed to different flow regimes, the results 
experienced interesting variations. While SMC reaction to flow remained the same, the 
reaction of EC and EC/SMC constructs diverged from the intact data. EC, surprisingly, were 
much less thrombogenic under oscillatory conditions than under static or arterial flow, which 
75 
4 – ENVIRONMENT-DEPENDENT THROMBOSIS BIOMARKERS IN EC AND SMC 
had the highest levels of clotting. Contrariwise, the EC/SMC constructs were more 
thrombogenic when the samples were exposed to oscillatory flow, but less when in the static 
controls. These data can only be explained by a counter-balance between re-
endothelialization and TF expression by cells in contact with blood flow. One may hypothesize 
that OF promotes both TF expression, but also re-endothelialization. If SMC are present, 
clotting would be higher due to increase in TF from SMC, but if absent, EC recover faster the 
metal strut and the surface exposed to flow. Only the re-endothelialization experiments in 
chapter 4.1.4 can confirm these hypothesis. 
 
Figure 102 - Images of the thrombogenicity assays in EC, SMC or SMC/EC co-culture exposed 
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Figure 103 - Thrombogenicity assays in EC, SMC or SMC/EC co-culture exposed to arterial 
flow (AF), oscillatory flow (OF) or static controls (STA) and injured with a metal stent (BMS) 
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4.1.4 – Re-endothelialization 
Stent re-endothelialization was evaluated in constructs coated with EC on top of SMC co-
cultures that were injured with bare metal stents. After NIR stent deployment at 16 atm, the 
constructs were exposed to arterial-like flow, oscillatory flow or static condition for 24 hours. 
Stent injury was visually confirmed at time 0 (Figure 104, Figure 105) and the luminal coverage 
of the stent was evaluated after 24 hours of exposure to the different flow regimes 
(Figure 106). Data for the abluminal side (Figure 107) confirmed good apposition of the stent 
against the wall of the constructs. In parallel, total cellularization and the EC/SMC ratio was 
quantified. Finally, TF expressed by SMC populating the stent was also determined in the 
different scenarios (Figure 108). Re-cellularization of stents followed an interesting trend. 
Oscillatory flow had a 75% higher cellularization than the arterial flow and static cases 
(Figure 109). This may lead to think that OF benefits stent re-endothelialization and hence 
reduces thrombotic risk. Looking closely to the EC/SMC ratio (Figure 111), however, one 
observes that OF promotes SMC occupation of the stent strut. This directly leads to the effect 
observed in Figure 110. TF exposed to blood flow in the luminal side is the highest in oscillatory 
regimes. Furthermore, as seen in chapter 4.1.1, Figure 83, SMC exposed to OF showed higher 
TF expression. This increase in TF expression explains thrombogenicity results observed in 
chapter 4.1.3 (Figure 102 and Figure 103), in which co-cultured, stented constructs presented 
larger blood clots when exposed to oscillatory regimes. These results have direct impact in 
stent implantation: the majoritarian presence of SMC on the stent struts implanted in 
oscillatory regions can promote restenosis and thrombosis. Contrariwise, stent struts placed 
in regions of artery-like flow, although they might re-cellularize later, promote EC growth 
predominantly, reducing the risk of stent thrombosis and restenosis. In any case, if a stent 
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were to be placed in an oscillatory region, the indication would be to minimize endothelial 
damage to limit SMC (and hence TF) exposure to flow. 
 
Figure 104 - Stent and balloon abluminal injury in EC/SMC (DAPI, blue) coated construct 
 
Figure 105 - 3D projection of a stent apposition on the abluminal side of an EC/SMC (DAPI, 
blue, TF, yellow) coated construct 
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Figure 106 - Luminal side of a stent 24 hours after deployment in an EC/SMC (DAPI, blue, 
CD31, green) coated construct 
 
Figure 107 - Abluminal side of a stent 24 hours after deployment in an EC/SMC (DAPI, blue, 
CD31, green) coated constructs 
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Figure 108 - Stent cellularization 24 hours after deployment in EC (CD31, green) / SMC (TF, 
red) coated constructs as a function of flow regime 
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Figure 109 - Stent cellularization as a 
function of flow regime 
 
Figure 110 - TF expression of cells on the 
luminal side of the stent as a function of flow 
regime 
 
Figure 111 - Ratio EC/SMC on top of stent struts as a function of flow regime 
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4.2. – Uremia related risk factors 
As described in chapter 1.4, uremic patients are at amplified risk of thrombosis when subject 
to stent implantation. This section will evaluate the effect of uremic milieu in thrombosis 
biomarkers such as TF expression and activity. As already seen in Figure 76, TF expression in 
quiescent EC is not in the detectability range while SMC is. Increased baseline SMC TF is 
consistent with the highest amount of clot formation observed in the SMC-coated flow loop 
tubes (Figure 100). In consequence, mono-cultured SMC, model of endothelial denudation 
after intervention, will be used to evaluate thrombosis biomarkers in uremic milieu. 
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4.2.1 – TF expression 
SMC were exposed for 24 hours to 5% serum pooled from end stage renal diseases patients 
suffering from uremia in DMEM (uremic serum) and compared to SMC exposed to 5% serum 
pooled from healthy volunteers conditions in DMEM (control serum). Results revealed that 
uremic serum doubles TF expression in SMC when compared to control serum (Figure 112). 
Furthermore, TF localization is altered. TF is mainly located in the cellular membrane of 
untreated or exposed to control serum SMC. In the case of uremic serum, remarkably, TF is 
not only located in the cell membrane, but is also intense in the cell nucleus. On the one hand, 
one could think that TF in the cell membrane has migrated to the nucleus as observed in other 
proteins that signal proliferation88, 102. On the other hand, uremic serum may be causing high 
levels of TF translation at nuclear level and what is observed in the picture would be TF ready 
to traffic towards the membrane54. 
 
Figure 112 - TF expression in SMC exposed to control serum (left) and uremic serum (right) 
Uremic solutes are the products of intermediate metabolism or retained proteins that failed 
to be fully excreted. The effect of a selected group previously linked to vascular dysfunction103 
of water soluble and protein-bound solutes in SMC TF expression was evaluated individually. 
Uric acid, the most significant water soluble solute, was evaluated with sodium hydroxide as 
a negative control (Figure 113). Among protein-bound solutes, indoxil acetate (IA), indoxil 
sulfate (IS) and homocysteine were chosen, with human serum albumin (HSA) as negative 
control. SMC were exposed for 24 hours to those solutes or their respective controls 
(Figure 114). While homocysteine had no significant effect on TF expression, uric acid, IA and 
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IS increased 2.3- to 3.5-fold compared to their respective controls. The mechanisms by which 
TF expression is higher in IA, IS and uric acid cases were further studied by Chitalia et al43. 
Briefly, IA and IS increased the stability of TF by interfering with its ubiquitination process, 
increasing TF levels. Potentially, their indole ring may be able to interfere in TF binding with 
its putative E3 ubiquitin ligase. The mechanism of UA-mediated TF regulation remains elusive. 
Uric acid did not significantly affect neither TF mRNA nor protein stability. It is possible that 
uric acid regulates TF translation or that it triggers an inflammatory response, indirectly 
regulating TF production. All of these possibilities warrant further investigation and prove the 
complexity of the effects of uremic solutes on TF regulation and are beyond the scope of this 
thesis. 
 
Figure 113 - TF expression in SMC exposed to sodium hydroxide (left) and uric acid (right) 
 
Figure 114 - TF expression in SMC exposed to different protein-bound solutes 
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4.2.2 – TF activity 
The flow loop assay described in chapter 5.3 was used to determine thrombogenicity in 
straight tubes coated with SMC. Cells were exposed for 24 hours to uremic serum, uric acid, 
IA, IS or their respective controls, control serum sodium hydroxide (NaOH) or human serum 
albumin (HSA), respectively. In a second set of experiments, cells were exposed to the 
treatment (uremic serum, uric acid, IA, IS) and incubated for 1 hour with control antibody or 
anti TF antibody. Figure 115 shows examples of the different clots and Figure 116, Figure 117, 
Figure 118 and Figure 119 show the normalized hemoglobin levels for each experiment. 
 
Figure 115 - Thrombogenicity in SMC-coated tubes exposed to uremic serum and uremic 
solutes  
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Figure 116 - Thrombogenicity of SMC exposed to uremic serum 
 
Figure 117 - Thrombogenicity of SMC exposed to uric acid 
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Figure 118 - Thrombogenicity of SMC exposed to indoxil acetate 
 
Figure 119 - Thrombogenicity of SMC exposed to indoxil sulfate 
SMC-coated constructs were consistently more thrombogenic when exposed to uremic serum 
(2-fold increase), uric acid (4-fold increase), IA (2.5-fold increase) and IS (2.5-fold increase). 
These results are in accordance with those observed in Figure 112, Figure 113 and Figure 114, 
correlating TF increase with augment of thrombogenicity. To confirm that thrombogenicity 
was activated through the extrinsic coagulation pathway, the treated SMC constructs were 
incubated with control antibody or anti-TF antibody. The increase in thrombogenicity was 
muted as TF was blocked by the antibody, confirming the hypothesis that TF was responsible 
for the observed increases in thrombogenicity. 
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5 – MATERIALS AND METHODS 
5.1 – Cell Culture 
5.1.1 – Materials and reagents 
CS: Calf Serum, mycoplasma tested, virus tested and endotoxin tested (Life Technologies, 
16170-078, New Zealand) 
Dextran: Dextran from Leuconocstoc mesenteroides (Sigma, D5376, US) 
DMEM: Dulbecco’s Modified Eagle Medium with low glucose  with L-glutamine, 25mM 
HEPES buffer, 110mg/mL sodium pyruvate, pyridoxine hydrochloride (Life Technologies, 
12320-032, US), with 5% CS and 1% PSG added and filtered with a 0.22μm filter to sterilize it. 
EGM-2: Endothelial cell Basal Medium-2 bulletkit (Lonza, CC-3162, US) with FCS 0.02 mL/mL 
supplemented with EGF-1 5 ng/mL, bFGF 10 ng/mL, Long R3 IGF 20 ng/mL, VEGF-165 0.5 
ng/mL, Ascorbic Acid 1 μg/mL, Heparin 22.5 μg/mL , Hydrocortisone 1 μg / ml, 5% FBS and 
1% PS and sterile-filtered with a 0.22μm filter. 
FB: Human aortic adventitial fibroblasts, cryopreserved cells (Cat. No. C-12380, Promocell, 
Germany)  
FBS: Fetal Bovine Serum (Life Technologies, 26140-079, US) 
Fn: Fibronectin from bovine plasma (Sigma-Aldrich, F4759, US) 
SMC: Human Aortic Smooth Muscle Cells, cryopreserved cells (Cat. No. PCS-100-012, ATCC, 
US) 
EC: Human Coronary Artery Endothelial Cells, cryopreserved cells (Cat. No. C-12221, 
Promocell, Germany) 
PBS: Phosphate Buffer Saline, pH 7.4 at 25ºC (Life Technologies, 70011-044, US) 
PS: Penicillin10000 units/ml penicillin G sodium with Streptomycin 10 mg/mL streptomycin 
sulfate in 0.85% NaCl (Life Technologies, 25030-081, US) 
PSG: PS with L-glutamine-200mM, 29.2 mg/mL in 0.85%NaCl (Life Technologies, 25030-081, 
US) 
TRYPSIN: 0.05% Trypsin in 0.53mM EDTA (Life Technologies, 25300-054, US) 
NIR Stent: Stent NIR® ELITE 15 mm x 3.5 mm, 7 cell, 316 stainless steel (Medinol, Product 
Number NIR® Elite OTW H7493486015350, US) 
Cordis BMS: Cordis® Bx Velocity Stent, 18mm x 3.5 mm 
Cordis DES: Cordis® Cypher Stent, 33mm x 3.5 mm, sirolimus-eluting stent 
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5.1.2 – Equipment 
COULTER COUNTER: Particle counter and size analyzer, Coulter Z2 (Coulter 
Corporation, US) 
CENTRIFUGE: G9095 IEC Model CL Centrifuge (IEC, US, 428). Rotor 215: 4x50ml, 
RCF 1750 g, Max Speed 3350rpm 
OM: Optical Microscope, Nikon Diaphot inverted tissue culture microscope 
FM: Fluorescence Microscope, Nikon Eclipse TE epifluorescence microscope coupled to a 
Hamamatsu CA 4742-95 camera 
CM: Confocal Microscope, Perkin-Elmer spinning disk confocal system coupled to a Zeiss 
Axiovert 200M microscope and a Hamamatsu Orca ER camera 
 
5.1.3 – Cell culture on plates 
Cryopreserved human coronary artery endothelial cells (EC), human aortic smooth muscle 
cells (HASMC) and human aortic adventitial fibroblasts (FB) were thawed, seeded, grown and 
passaged onto 100mm tissue culture polystyrene plates (TCP100) as follows. The same 
procedure was followed for each cell type. 10 mL of previously warmed EGM-2 for EC and FB 
or DMEM for SMC were poured into a TCP100. Then, a 2mL cryovial containing about 1.3 
million cells was thawed in the water bath at 37ºC for less than 2 minutes and poured in the 
TCP100. The TCP100 was placed in the 37ºC incubator, at 5% CO2. After 4-5 hours, the 
attachment of the cells was visually confirmed under the optical microscope and culture 
medium was replaced with 10mL of fresh medium. Every 2-3 days, culture medium was 
replaced by 10mL fresh medium, visually checking cells’ health under the optical microscope; 
culture plates were kept in humidified incubator while not being manipulated. Once the cell 
surface coverage reached 95% of the plate, cells were passaged in a ratio 1:3 to continue with 
their culture. Supernatant was removed and cells were rinsed with 10mL PBS. After aspirating 
off PBS, 3mL of Trypsin were poured on the cells and incubated during 5 minutes. Then, 7mL 
of DMEM were added to the plate in order to neutralize the effect of trypsin. The content of 
the plate was transferred into a 50mL Falcon® tube, and the plate was rinsed with additional 
5mL of DMEM, transferring again the content of the plate into the same tube. The cell 
suspension was centrifuged for 5 minutes at 2000 rpm and then the supernatant medium was 
removed, keeping only the cell pellet. The pellet was resuspended in 30mL of corresponding 
medium and split into three new TCP100.  
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5.1.4 – Cell culture on tubes and constructs 
Flow experiments required culturing cells on the luminal surface of tubes or bifurcated 
constructs. After culturing enough cells for the experiments (≈2-5 million cells/TCP100), cells 
were seeded and cultured on straight tubes and bifurcations following the procedure detailed 
below. Prior to cell seeding, tubes or constructs were washed in 0.2% SDS for 20 minutes, 
rinsed twice with distilled water for 20 minutes and autoclaved. Tubes were coated with 100 
(straight tube, coronary bifurcation) or 150µg/ml (carotid bifurcation) fibronectin (Fn) in PBS 
overnight at 4ºC. A cell suspension was prepared as described above and resuspended at 1 
million cells/mL. FB, SMC and EC were sequentially layered with 48h of difference between 
strata. In order to ensure homogeneous distribution of cells along the inner surfaces of tubes 
and bifurcations, tubes and constructs were placed in a cylindrical, 25cm diameter rotator 
turning at 3 rpm inside a 37ºC, 5% CO2 humidified incubator. After this process, tubes or 
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5.1.5 – Stenting 
Before exposure to flow, some experiments required stenting the cell-seeded constructs 
(Figure 120). A catheter with a 3.5mm-wide, 16mm long NIR® elite stent mounted on an 
inflatable balloon was introduced through the construct. The balloon was inflated at 16 gauge 
atm, so the deployed stent remained well apposed on the silicone construct (Figure 121). The 
balloon was then deflated to -0.5 gauge bar and the catheter retrieved.  
 
 
Figure 120 - Overall vessel-like seeding and stenting process 
 
Figure 121 - Stented straight construct 
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5.2 – Perfusion Bioreactor 
The perfusion bioreactor is a flow delivery system designed to provide the tubular constructs 
with any flow type (steady, pulsatile, oscillatory) and to enable study of how cells react to 
different flow stimuli. It was designed coupled to a humidified incubator (37ºC, 5% CO2) where 
tubing and cell-seeded constructs are placed and connected to flow. Flow is driven by analogic 
pumps consisting of a digital drive (Cole Parmer, EW-78002-00) and a pump head with 12 
channels and 8 rollers (Cole Parmer, EW-78002-36). A program in LabView® previously created 
by Dr. Peter Wu generated an electrical signal adjusted with a customized manual control to 
generate the desired flow waveform. Only the pump drive was placed outside the incubator, 
while pump head and tubing remained inside. The original incubator by Thermo Scientific had 
to be modified to connect the pump heads to the tubing system. Holes were drilled to allow 
the pump’s transmission through the water jacket until the pump head. The modifications 
were designed using Autocad® and Thermo Scientific executed the proposed modifications. 
Similarly, the trays were redesigned to allow space for the pump head and proper positioning 
of the reservoirs. The setup used to propel flow through the construct differed as a function 
of the type of construct studied. Generally (Figure 122), the reservoir was connected to a 10-
cm long 4.78 mm ID Silastic® tube (Dow Corning – Cat No. 515-013) and attached to two-stop 
pump Pharmed BPT tubing, ID 2.79mm (Cole-Parmer, 95713-48) with 1/8” ID straight 
connectors (Cole-Parmer 30703-02). For carotid constructs (Figure 124), the system was 
divided into four channels so the pump delivered four times the maximal flow and merged 
into a single channel before entering the cell-seeded construct. After flowing through the 
carotid scaffold, medium returned to the reservoirs by merging the two outlets. 3.18 mm ID 
Silastic® tubes (Dow Corning – Cat No. 515-012) and Y connectors (Cole Parmer – Cat No. EW-
40727-41) were used. For coronary constructs (Figure 125) and straight tubes (Figure 123), 
the system used a single two-stop pharm tube to reach the flow rates and the systems 
followed the schemes in (coronary) and (straight tube). The static loops were 15 cm-long 4.78 
mm ID Silastic® tubes connecting both extremes of the cell-seeded construct. Straight vessel-
like constructs and bifurcated constructs were connected to the perfusion bioreactor as seen 
in Figure 123, Figure 124 and Figure 125. Straight tubes were exposed to coronary artery–like 
flow, oscillatory flow or static conditions. AF was 1-Hz pulsatile flow of 17 dyne/cm2 maximal 
shear stress and OF was 1Hz oscillatory flow of 5 dyne/cm2 maximal shear stress. In the 
coronary model, medium flowed at 1 Hz pulses with 17 dyne/cm2 maximal shear stress. In the 
carotid model, flow pulsed at 1 Hz with 12 dyne/cm2 maximal shear stress. 
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Figure 122 - General connection scheme of the bioreactor 
 
Figure 123 - Straight tubes connection scheme 
 
Figure 124 - Carotid constructs connection scheme 
 
Figure 125 - Coronary constructs connection scheme 
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5.3 – Thrombogenicity device 
A modified Chandler loop evaluated endovascular device thrombosis. Motor-controlled rotors 
accelerate blood-filled flow loops (Figure 126), generating pulsatile flow simulating coronary-
like hemodynamics (peak flow, 100 mL/min). A flow loop consisted of 4 cm-long, 1/8” ID 
Tygon® 3350 tubes (Saint-Gobain, France) coated with vascular cells (prepared and seeded as 
described in chapter 5.1.4). The loop was subjected to a coronary flow condition that emulates 
the endovascular intervention ex vivo and serves as a screening tool to examine thrombosis 
in various vascular beds. Before cell seeding, Tygon® tubes were cleaned and autoclaved and 
injected with one million cells/mL of SMC or EC into fibronectin-coated tubes and cultured for 
48 hours under axial rotation at 10 rph, 37°C, 5% CO2. Cell seeded tubes were exposed to 
different arterial flow types or kept static (no flow) as control or when evaluating the effect of 
uremic serum and uremic solutes. The exposure time for the different stimuli was always 24 
hours. The segments were explanted, gently flushed to remove the media, and positioned in 
the reactive site flow loop model as seen in Figure 127. 
 
Fresh whole blood was collected from healthy volunteers in a 10% acid/citrate dextrose 
solution (0.085 M trisodium citrate, 0.069 M citric acid, 0.111 M glucose, pH 4.6). Immediately 
before testing, a 0.1 M CaCl2 and 0.075 M MgCl2 solution was added to the blood (70-μL 
solution per 1 mL blood) and loaded into the flow loops. After 10 to 15-minute runs, loops 
were emptied and flushed with 60 mL Tyrodes buffer (0.01 M HEPES, 0.75 M MgCl2) to remove 
non-adherent material. After visual assessment, the clot was lysed with 1% Triton-X solution 
for 20 minutes. Lactate dehydrogenase and hemoglobin were measured with the use of 
Quantichrome heme assay and Cyto-Tox 96 nonradioactive cytotoxicity assay (Promega) as 
measures of erythrocyte content and total clot mass, respectively. 
 
TF neutralizing assay was performed as follows. After SMC-coated tubes were exposed to 
uremic serum or uremic solutes for 24 hours, the constructs were treated with isotype control 
antibody anti-Iba1 (Santa Cruz Biotechnology) or anti-TF neutralizing antibody (50 μg/mL) 
(American Diagnostica) for 1 hour at 37ºC and 5% CO2 before the flow loop experiment. 
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Figure 126 - General two-axis system schematic and fluid loop design75 
 
Figure 127 - Close-up of the flow loop and the reactive site76 
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5.4 – Monocyte isolation and adhesion 
Fresh blood was drawn from healthy male 
subjects (Blood research components) and 
shipped with 10% EDTA. The blood was mixed 
1:1 with a PBS/EDTA solution (0.5 M EDTA in PBS) 
and homogenized. The blood/PBS/EDTA solution 
was very carefully layered onto the same 
amount of Histopaque 1077 (Sigma) in order to 
avoid the mixing of the two liquids. The resultant 
bilayered tube was centrifuged at 400g for 30 
minutes at room temperature. The result of the 
centrifugation is shown in Figure 128. 
 
 
Figure 128 - Blood/PBS/EDTA/Histopaque 
1077 mix after centrifugation
After centrifugation, supernatant plasma was carefully aspirated and discarded. With a 
pipette, the peripheral blood mononuclear cells (PBMC) – typically 5 mL – were transferred 
into another centrifugation tube and 10 mL of EDTA/PBS were added. This tube was spun at 
400g for 10 minutes and the supernatant was discarded. The pellets from every tube were 
gathered by resuspending them in the same 10 mL of PBS/EDTA. The concentration of 
mononuclear cells was evaluated by cell counting and the suspension was centrifuged again 
for 10 minutes and concentrated. Monocytes were isolated from PBMC by negative selection. 
Non monocytes were magnetically labeled with a cocktail of biotin-conjugated antibodies that 
were recognized by an anti-biotin antibody conjugated to magnetic beads (Miltenyi Biotec).  
 
The concentrated pellet of mononuclear cells was dissolved in a mix of 1 μL blocking 
reagent/million PBMC, 1 μL primary antibody/million PBMC  and 30 μL of PBS/EDTA/iFBS (1% 
inactivated FBS in PBS/EDTA). After vortex and 10 minutes of incubation 4 °C, 2 μL secondary 
antibody/million PBMC were added to the mix. After vortex, the mixture was incubated for 15 
minutes at 4 °C. Cells were subsequently washed with 10 mL of PBS/EDTA and centrifuged at 
400 g for 10 minutes. The supernatant was discarded and the pellet was resuspended in 1 mL 
of PBS/EDTA/iFBS. A magnetic column (MACS) was placed on the magnetic support and 
equilibrated by rinsing it with 1 ml PBS/EDTA/iFBS). The cell suspension was ran through 
column twice and the eluent containing the isolated monocytes was recollected at the 
bottom. The column was washed with 500 μL of PBS/EDTA/iFBS and the entire effluent of the 
washing steps was gathered and mixed with the monocyte solution. After counting, isolated 
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monocytes were mixed with EGM-2, injected in the tissue culture plates or constructs at a 
density of 1 monocyte/endothelial cell and incubated at 37ºC and 5% CO2 for 2 hours. EC 
within the tubes or constructs had previously been exposed to medium supplemented with 
TNF-α for 24 hours. Thereafter, the constructs were rinsed with PBS, fixed and stained for α-
tubulin and DAPI. Fluorescent images were obtained at 405nm and 640nm. The ratio of 
adhered monocytes was quantified by analyzing the obtained IF images. 
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5.5 – Microscopic examinations 
For IF, tissue culture plates or constructs were rinsed with PBS and fixed with 4% 
paraformaldehyde for 30 minutes at room temperature. Excessive aldehydes were quenched 
with 0.2M glycine in PBS for 10 minutes and, after washing with PBS, cells were permeabilized 
with 0.2% X-100 Triton in PBS. After two consecutive washes with PBS for 10 minutes and 1 
hour blotting with 5% goat serum in PBS-BSA (PBS, 1% bovine serum albumin), cells were 
labeled overnight at 40C with their respective antibodies, generally diluted 1:50 in PBS-BSA. 
Cells were rinsed twice with PBS-BSA for 10 minutes and stained with the appropriate 
secondary antibodies and DAPI solution (1:100 in PBS-BSA) for 2h. Two additional 10 minutes 
washes with PBS were performed to remove any unbound antibody. Specimens were imaged 
using a Nikon Eclipse TI-E epifluorescence microscope or a Perkin-Elmer spinning disk confocal 
system coupled to a Zeiss Axiovert 200M microscope. The list of antibodies used is detailed in 
chapter 5.7. 
 
For SEM, cells on constructs were first fixed in 3% glutaraldehyde, rinsed with PBS and 
subjected to a series of dehydration steps, which included 30 minutes incubations in ethanol 
solutions of increasing content in ethanol (50, 70, 95 and 100%) and 1h in acetone. Specimens 
were air dried overnight, sputter coated for 45s using a Denton (Mooretown, NJ) Vacuum Desk 
II Sputter Coater and imaged with a Hitachi (Tokyo, japan) S-3400N scanning electron 
microscope. 
 
For H&E, cells on constructs were fixed in 4% PFA and subjected to a series of infiltration steps, 
which included 24 hours incubations in Spurr’s resin (Electron Microscopy Sciences, Hatfield, 
PA) solutions in ethanol solutions of increasing content in Spurr’s resin (25, 50, 75, 95, 100%). 
The resulting blocks were sampled and micro ground using an EXAKT 400CS Micro Grinding 
System (EXACT, Norderstedt, Germany) progressively until a 70-80 μm thickness. The samples 
were finally observed using an optical microscope.  
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5.6 – Radioimmunoprecipitation assay (RIPA) and western blot analysis 
Non-specific cell lysis was performed by rinsing cell-coated constructs twice with ice cold PBS 
and then incubating them for 30 minutes on ice in radioimmunoprecipitation assay buffer 
containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS and 5 mM EDTA. The supernatant was extracted after centrifugation for 30 minutes at 
13000 g and 4ºC, and mixed with 1:4 v/v of Laemlli’s buffer (Boston Bioproducts) with 8% 
mercaptoethanol (Sigma). 10% acrylamide gels (Life Technologies) were used for protein 
separation. Gels were blotted using Life Technologies gel transfer stacks and blotting system. 
Membranes were blocked with 5% powdered milk and incubated overnight at 40C while 
shaking with the antibodies of interest diluted at their optimal concentration. After two 
washes with PBS-T (PBS, 0.05% Tween20, Sigma), membranes were incubated with 
appropriate HRP-conjugated secondary antibodies diluted 1:2,000 for 1h while shaking at 
room temperature. After two 10 minutes washes in PBS-T, LuminataTM Forte Western HRP 
Substrate (Milipore) was applied and luminescence was detected in a Chemidoc XRS+ (Bio-
Rad). Densitometry plots were analyzed using ImageJ (NIH). 
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5.7 – Antibodies 
Table 2 and Table 3 summarize the primary and secondary antibodies used for 
immunofluorescence (IF) and western blot (WB) and their respective dilutions. 
 
Primary antibodies IF dilution WB dilution 
Mouse monoclonal anti-CD106 (Santa Cruz Biotechnology) 1:50 1:50 
Mouse monoclonal anti-TF (Sekisui Diagnostics) 1:50 1:1000 
Mouse monoclonal anti-α-smooth muscle cell actin (Sigma) 1:50 N/A 
Rabbit polyclonal anti-CD31 (abcam) 1:50 N/A 
Rabbit polyclonal anti-CD54 (Cell Signaling) 1:50 N/A 
Rabbit polyclonal anti-Ki67 (abcam) 1:50 N/A 
Rabbit polyclonal anti-α-tubulin (Santa Cruz Biotechnology) 1:50 1:200 
Rabbit polyclonal anti-cytoglobin (Santa Cruz Biotechnology) N/A 1:200 
Table 2 - Primary antibodies used in IF and WB 
 
Secondary antibodies IF dilution WB dilution 
Alexa Fluor® 488 goat anti-mouse IgG (H+L) (Life 
Technologies) 
1:100 N/A 
Alexa Fluor® 488 goat anti-rabbit IgG (H+L) (Life 
Technologies) 
1:100 N/A 
Alexa Fluor® 568 goat anti-rabbit IgG (H+L) (Life 
Technologies) 
1:100 N/A 
Alexa Fluor® 647 goat anti-mouse IgG (H+L) (Life 
Technologies) 
1:100 N/A 
Alexa Fluor® 647 goat anti-rabbit IgG (H+L) (Life 
Technologies) 
1:100 N/A 
HRP goat anti-mouse IgG (H+L) (Bio-Rad) N/A 1:2000 
HRP goat anti-rabbit IgG (H+L) (Bio-Rad) N/A 1:2000 
Table 3 - Secondary antibodies used in IF and WB 
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5.8 – ELISA and TF activity assay 
The ELISA KIT 845 from Sekisui Diagnostics was used to determinate soluble TF in static 
experiments. The Human TF Activity Kit from Assaypro was used to determinate TF activity. 
After each experiment, culture medium was collected; cells were rinsed with PBS, detached 
with trypsin and counted using the Cell Counter. The collected medium was poured into 
Millipore® Centriplus 15 mL filters (10 kDa) and centrifuged for 30 minutes. One can easily 
obtain 1:10 dilutions with this method without drying the sample or losing signal quality. The 
medium outside of the filter was recovered and the medium inside was discarded; the 
medium able to go through the filter did not include TF (47 kDa) while the fraction that had 
not been through the filter contained TF more concentrated than initially. Initial and final 
volumes were computed to calculate concentration factor. Samples were collected and the 
standards were prepared. Remaining medium was stored at -80°C. 
 
For the ELISA kit, 100 μL of TF standard or sample was added to each pre-coated microwell 
and incubated overnight at 4°C in a refrigerator. The day after, wells were washed 4 times 
with wash buffer. Afterwards, 100 μL of detection antibody were added to each well and 
incubated for 1 hour at room temperature. Wells were washed 4 times with wash buffer. 100 
μL of diluted enzyme conjugate, a solution of 1 μL of conjugate per mL diluent, were added to 
each well and incubated for 1 hour at room temperature. After 4 washes, 100 μL of substrate 
solution were added to each well and the plate was incubated for 20 minutes at room 
temperature, developing a blue color. The reaction was stopped by adding 50 μL of 0.5M 
H2SO4 and the solution color turned yellow. Absorbances were read at 450 nm within 30 
minutes. The experiment was repeated by diluting or concentrating the original samples if 
results were not within the standard’s range. 
 
For the TF activity kit, all reagents and working standards were diluted following 
manufacturer’s instructions. The Assay Mix was prepared, consisting of 50 μL Assay Diluent, 
10 μL FVII and 10 μL FX for each sample or standard. On each well of the 96 well plate, 70 μL 
of the Assay Mix were mixed gently with 10 μL of TF Standard or samples and incubated at 
37ºC for 30 minutes. Afterwards, 20 μL of FXa Substrate were added and gently mixed. The 
absorbance at 405 nm was read at zero minutes for background OD. The plate was incubated 
at 37ºC and the absorbance read at 405 nm every 2 minutes for 12 minutes. The data with 
best signal to noise ratio before saturation were selected as final results. 
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5.9 – Numerical methods for simulations 
According to Equation 11 and Equation 12, parabolic velocity profile in arteries can ideally be 
modeled by a Gaussian distribution. In order to introduce this velocity profile in the CFD 
software, this function was adjusted using data from real patients. Equation 12 was slightly 
modified into Equation 15 by adding the constant base velocity observed in real patients. The 
maximal velocity of the parabola for one pulse now reads: 





Equation 15 - Adjusted velocity profile for one pulse in CFD simulations 
In this equation, vbase is the constant velocity, vbase + vpulse is the maximal velocity in the center 
of the artery, tpulse is the time of pulse and σ the width of the pulse. This equation applies to 
one pulse only. If multiple pulses want to be applied, the equation for the number of pulses 
npulse and the heart frequency frec in beats per minute is modified as follows: 








Equation 16 - Adjusted velocity profile for n pulses in CFD simulations 
The tangential component of the velocity vector (vTan), calculated as the dot product of its 
local velocity vector and the normalized direction vector representing the vessel centerline, 
was used as a measure of the velocity of the fluid flow. Based on this vTan metric the extent 
of flow recirculation was classified into three categories: severe, mild or negligible. If the 
maximal backwards velocity (vTanMIN) was above 20% of the inlet velocity during the pulse, 
the extent of recirculation was considered severe. If vTanMIN was between 5% and 20%, the 
extent was considered mild and negligible if the former criteria were not met. vTan was 
evaluated at each node and all the tetrahedrons containing at least one node with negative 
vTan were summed to estimate the “Total Recirculating Volume” (VolRec) for each branch 
(EQ). The parameter “Normalized vTan·VolRec” (NVV) was calculated multiplying VolRec by 
vTan and dividing it by the volume of the branch and normalizing it to the value of the straight 
segment of the bifurcation.  
VolRec = �(TetrahedronsvTan<0) 




(𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 · 𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉 𝐵𝐵𝑟𝑟𝑣𝑣𝑣𝑣𝑉𝑉ℎ )𝑆𝑆𝑆𝑆𝑆𝑆𝑚𝑚𝑖𝑖𝑆𝑆ℎ𝑆𝑆  𝑏𝑏𝑆𝑆𝑚𝑚𝑛𝑛𝑏𝑏ℎ
 
Equation 18 - NVV calculation 
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The diffusion of sTF was adimensionalized in order to reduce the simulation time. Although 
this underestimates the convective term of the mass transfer equation, it is an approach to 
the actual distribution when computing resources are limited. The adimensional number π1 
(Equation 19) proves that, given a diffusivity D, a mass flow ṁ increasing the viscosity µ of the 
fluid reduces the time tD that a solute needs to diffuse. 
π1 =
µ2 · D · tD
ṁ2
 
Equation 19 - Viscosity adimensionalization for diffusion time 
 
The arterial bifurcation design program has three different modules that require different 
inputs and return different outputs. Table 4, Table 6 and Table 8 present the geometrical 
parameters used for the arterial bifurcations studied; Table 5, Table 7 and Table 9 show the 
specific inputs for each module used. 
 
Dimension Length (mm) Width (mm) Ratio 
CCA 1 8 8 1 
CCA 2 32 8 1 
CCA 3 56 8 1 
CCA 4 80 8 1 
ICA 0 0 8.3 1 
ICA 1 7.28 8.9 1 
ICA 2 14.48 8.2 1 
ICA 3 24 6 1 
ICA 4 36 5.7 1 
ICA 5 45 5.7 1 
ECA 0 0 5.6 1 
ECA 1 15 5.5 1 
ECA 2 30 4.6 1 
ECA 3 45 4.6 1 
ECA Angle (º) 25.1 - - 
ICA Angle (º) 25.4 - - 
Table 4 - Geometrical parameters for the carotid bifurcation 
Module Parameter Value 
Simulation 
First Pulse (s) 1 
Pulse Width (s) 0.05 
Frequency (bpm) 60 
V base (m/s) 0.1 
V max (m/s) 0.6 
Mold Design Thickness (mm) 1 Tolerance (mm) 0.4 
3D Print Thickness (mm) - 
Table 5 - Specific inputs for the carotid bifurcation 
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Dimension Length (mm) Width (mm) Ratio 
LM 1 4 3.61 1 
LM 2 20 3.61 1 
LM 3 45 3.61 1 
LM 4 70 3.61 1 
LAD 0 0 2.8 1 
LAD 1 5 2.8 1 
LAD 2 12 2.8 1 
LAD 3 24 2.8 1 
LAD 4 40 2.8 1 
LAD 5 60 2.8 1 
LCX 0 0 2.77 1 
LCX 1 15 2.77 1 
LCX 2 30 2.77 1 
LCX 3 60 2.77 1 
LAD Angle (º) 31.5 - - 
LCX Angle (º) 31.5 - - 
Table 6 - Geometrical parameters for the flat coronary bifurcation 
 
Module Parameter Value 
Simulation 
First Pulse (s) 0.4 
Pulse Width 0.05 
Frequency (bpm) 60 
V base (m/s) 0.05 
V max (m/s) 0.8 
Mold Design Thickness (mm) 0.6 Tolerance (mm) 0.4 
3D Print Thickness (mm) 0.75 
Table 7 - Specific inputs for the flat coronary bifurcation 
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Dimension X Y Z Width (mm) Ratio 
LM 1 -9.474 29.159 37.000 3.61 1 
LM 2 -7.659 30.720 38.000 3.61 1 
LM 3 -6.138 31.579 39.000 3.61 1 
LM 4 -4.150 32.000 40.000 3.61 1 
LAD 1 -21.493 23.049 37.000 2.8 1 
LAD 2 -25.273 19.044 33.000 2.8 1 
LAD 3 -26.968 15.570 29.000 2.8 1 
LAD 4 -27.992 11.309 26.000 2.8 1 
LAD 5 -27.789 6.929 24.000 2.8 1 
LAD 6 -27.920 3.428 21.000 2.8 1 
LCX 1 -14.365 22.120 42.000 2.77 1 
LCX 2 -13.689 20.295 45.000 2.77 1 
LCX 3 -12.235 18.139 49.000 2.77 1 
LCX 4 -12.093 16.049 52.000 2.77 1 
Bif. Center -12.480 26.760 38.000 3.61 1 
Table 8 - Geometrical parameters for the curved coronary bifurcation 
Output Parameter Value 
Simulation 
First Pulse (s) 0.4 
Pulse Width (s) 0.05 
Frequency (bpm) 60 
V base (m/s) 0.05 
V max (m/s) 0.8 
Number of Pulses 2 
Mold Design Thickness (mm) - 
Tolerance (mm) - 
3D Print Thickness (mm) 0.75 
Support Thickness (mm) 0.75 
Tolerance (mm) 0.4 
Table 9 - Specific inputs for the curved coronary bifurcation 
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The numerical methods used to resolve the systems of equations shown in chapter 1.6 require 
a series of boundary conditions. GID gives a user-friendly environment to introduce these 
boundary conditions and other geometrical and mathematical resolution methods as 
parameters. Table 10 shows the parameters modified in the simulations run, the rest were 
left as default. These conditions, particularly meshing size and time increment are function of 
each particular problem. The table shows the values used in the coronary and carotid cases. 
Figure 129, Figure 130 and Figure 131 show the mesh density for each case studied. For sTF 
distribution, with a diffusivity of 2.05·10-11 m2/s, initial sTF concentrations were 2.2 ng/cell for 
the stented area and 0.7 ng/cell in healthy regions. These data were obtained by analyzing the 
released sTF in injured plates (chapter 4.1.2). 
 
 
Figure 129 - Carotid 
bifurcation’s mesh 
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GID Command Value 






Y=9. 81m/s2  (Flat Coronary) 
Z=9. 81m/s2  (Curved Coronary) 
Results 
Velocity, Pressure, Wall Shear Stress, Advection 
Results file: ASCII 
Fluid Solver Stab Bi-Conjugate 
Other Use Total Pressure: 101325 Pa 
Fluid properties 
Density 1035 kg/m3 
Viscosity 0.0035 kg/m.s 
Fluid boundaries 
Wall 
Bound. type VfixWall 
Angle 0.0 
Inlet 
Bound. type Inlet VelC 
VelY field Function of problem 
Outlet Press. field 0.0 Pa 
Analysis 
Time Increment 0.5 ms 
Number of steps Function of problem 
Maximal iterations 15 
Output 
Output Step Function of problem 




Central Vol: 0.25 
Ext Vol: 0.35 
Carotid 
Central Vol: 0.95 
Ext Vol: 0.7 
Size Transition 0.7 
Table 10 - Conditions for GID simulations 
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5.10 – Scaffold and support design 
5.10.1 – Teflon® molds CNC Manufacturing 
The positive molds manufacturing consisted of three processes, a “Roughing.1” followed by 
two consecutives “ZLevel.1”. The initial “Roughing” target was to do a rapid approximation to 
the geometry with a bigger tool, so the slower “ZLevel.1” would be shorter and more precise. 
The “Roughing” smoothed down the Teflon® pad at a radial stepover of  1/50 tool diameter 
ratio, with a machining tolerance of 0.1mm, using with a flat-end tool of 8mm diameter, 
spinning at 1000 rpm (c.f. Figure 5.6.1.1). Once finished, a first “ZLevel.1” dug along the 
geometry, digging at a constant stepover of 0.025mm, and a scallop height of 0.025mm, until 
the whole geometry was drawn. The definitive “ZLevel.2” had to be programmed to polish the 
figure because nor the “Roughing” nor “ZLevel.1” were able to correctly rough the area next 
to the bifurcation. The particular condition for “Zlevel.2” was 1mm offset both on the “Part” 
(whole geometry) and the “Check” (area near the bifurcation). In both “ZLevel.1” and 
“ZLevel.2”, the machining tolerance was 0.1mm, using a ball-end tool of 2mm diameter, 
spinning at 3000 rpm. (cf. Figure 5.6.1.2). The Fagor® 8055 lasted about 45 minutes to finish 
the complete manufacturing.  The cuvette manufacture consisted in a unique “ZLevel.1” 
process, which dug along the geometry, digging at a constant stepover of 0.025mm, and a 
scallop height of 0.025mm, until the whole geometry was created. The tolerance of the 
machining was 0.1mm using a ball-end tool of 2mm diameter, spinning at 3000 rpm. The 
Fagor® 8055 lasted about 3 hours to finish the manufacturing. 
 
Figure 132 - Coronary artery positive mold 
after “Roughing” 
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5.10.2 – Photo-polymeric scaffold 3D Printer 
After running the Visual Basic® program in 3D Print module, an STL file with the desired 
geometry is generated. STL is the format used by 3D Printers to cast prototypes. The STL file 
generated was sent to ZSI, a company that gives the possibility to lend its 3D Printers. The 3D 
Printer used is the Objet Eden 500V. This printer offers a print resolution of 42 µm in the X 
and Y axis and 16 µm in the Z axis. It has a thickness limitation of 0.6mm. The material 
polymerized is called FULLCURE® 930 TANGOPLUS, consisting in a mix of urethane acrylate 
oligomer (30 to 60%), methacrylate oligomer (10 to 30%), Exo-1,7,7-
trimethylbicyclo[2.2.1]hept-2-yl acrylate (10 to 30%), polyurethane (10 to 30%),  and a photo-
initiator (0 to 1%). The 3D printer sequentially added the liquid mix in a layer-by-layer manner, 
using UV light to polymerize and solidify the mixture. At the same time, the printer creates a 
polymeric support to ensure the stability of the scaffold. The support is dissolvable in 1 M 
sodium hydroxide at 37ºC and overnight agitation. 
 
5.10.3 – Polycarbonate support 3D printer 
The STL file from the square support module of the Visual basic interface was adapted and 
prepared by the software Insight® and sent to a Fortus 400mc (Stratasys) 3D printer that 
casted the polycarbonate supports for curved coronary bifurcations. This 3D printer uses fused 
deposition modeling (FDM) technology to cast its prototypes. Briefly, a plastic filament or 
metal wire is unwound from a coil, supplying material to an extrusion nozzle which can turn 
the flow on and off. The nozzle is heated to melt the material and can be moved in both 
horizontal and vertical directions by CNC and directly controlled by a computer-aided 
manufacturing (CAM) software package. The model is produced by extruding small beads of 
thermoplastic material to form layers, as the material hardens immediately after extrusion 
from the nozzle. In order to print the parts of the geometry that are suspended and could 
collapse before hardening, a support is printed (with the same material as the model, or a 
different one). Once the whole geometry has been 3D printed, all the supports are removed.  
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5.11 – Microparticle tracking 
The following steps were carried out to follow microparticles flowing through the PDMS 
scaffolds. The studied scaffold was connected to 3.18 mm ID Silastic® tubes with two reservoirs 
and a peristaltic pump (Ismatec Ecoline VC-360) completing the circuit, as seen in Figure 134. 
The scaffold was placed under an optical microscope coupled to a recording camera Genie 
HM640. The circuit was filled with a water solution containing 20 g/L of dextran and 0.3 g/L of 
polyethylene microparticles (Cospheric, ID: BLPMS 27-45 µm, 1000 kg/m3). Finally, the pump 
was connected in order to fill the reservoir 1 and make the liquid flow through the bifurcation. 
The fluid’s velocity was regulated by varying the height of the reservoir 1. The microparticles 
trajectories were recorded by the camera and tracked with the software “Tracker 4.62”. This 
process was repeated at different fluid velocities and with the carotid and flat coronary 
scaffolds. 
 
Figure 134 - Microparticle tracking experimental setup 
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5.12 – Statistical Analysis 
The in vitro experiments described were performed at least by triplicate and repeated two to 
four separate times. In graphical presentations, data are expressed as average ± standard 
error of the mean and * or # means significant difference between averages. Kruskal-Wallis 
one-way analysis of variance followed by Scheffé’s method post-hoc analysis was conducted 




6 – CONCLUSIONS 
6 – CONCLUSIONS 
A Visual Basic® 2010 framework was developed to replicate vascular bifurcations. The 
framework created the specific computer aided design files for CFD simulations, for mold 
manufacture using computer numeric control, and for polymeric scaffold manufacturing using 
photopolymeric 3D-Printers. Using conventional medical imaging techniques, arterial 
geometries of different patients were reconstructed based on the extracted geometric 
features. The files were used to run computational flow simulations that predicted velocity 
distributions and identified regions of flow recirculation and stagnation. A scalar metric (NVV) 
was defined to capture the extent of recirculation for a patient-specific geometry. The 
interface was also used to cast in vitro models of the coronary and carotid bifurcations that 
were manufactured in PDMS. Simulating patient-specific, physiologic conditions, endothelial 
cells and/or smooth muscle cells were sequentially layered and remained functional on the 
polymeric substrate.  
 
Vascular health is a complex fingerprint of many factors that can be identified with markers 
of proliferation to give a sense of growth, expression of critical proteins give a sense of 
synthetic function and responsive genes and surface molecules to indicate sensitivity. Bench-
top derived measurements of atherogenic and thrombotic markers and their geometry-
specific variations were correlated with the model-based predictions. More specifically, 
VCAM-1 expression, Ox-LDL uptake and monocyte adhesion were chosen as biomarkers for 
atherogenesis, and tissue factor was chosen as predictor of thrombotic phenotype.  
 
The full sequence of atherogenesis was activated in the regions of flow recirculation and 
stagnation. We also observed that not only flow disruptions exacerbated vascular disease 
indicators, but arterial flow promoted endothelial health, independently of the studied 
arterial bed. In particular, the amount of recirculation correlated with monocyte adhesion to 
activated endothelial cells and Ox-LDL uptake by quiescent endothelial cells. The expression 
of VCAM-1 rose when quiescent endothelial cells were exposed to flow disruptions, but this 
increase was muted when cells were activated with inflammatory agents. Further, tissue 
factor expression and thrombogenicity in SMC increased very significantly in subjects 
associated with a larger extent of recirculation. Soluble tissue factor from injured arterial walls 
predominantly nested on regions of flow recirculation. These observations highlight the 
importance of accounting for patient-specific geometry variations and flow derangements to 
extend the derived biologic inferences well beyond idealized cell culture models to real world 
settings. Furthermore, the data suggests that practitioners should take into account the local 
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recirculation as a critical parameter to define the parameters of stent placement, focusing on 
minimizing endothelial denudation especially in regions of flow recirculation. 
 
Simplified straight channel models lack the spatial resolution of the different regions of a 
bifurcated artery. While all of the inflammation and thrombogenic biomarkers generally rose 
when cells were exposed to oscillatory flow and static conditions, these values showed a clear 
correlation with the local amount of recirculation for each branch on each arterial bed. Our 
model analyzes locally the recirculation extent and compares values between cells that are 
genetically identical and exposed to the same solutes. The main factor that varies among these 
cells is the amount of recirculation, which ends up altering the vascular cell phenotype. The 
three-dimensional approach localizes better the impact of the flow patterns but poses novel 
challenges at the same time. The studied biomarkers presented levels near the detection 
thresholds of the analytical methods applied, especially in small sections such as the 
recirculation regions of the bifurcated constructs. This limits, i.e., the study of TF in EC and the 
differentiation in signaling from SMC vs. EC in a bilayer such as the one described. 
 
Not only are the fluid dynamics of the vessel crucial in determining thrombotic and 
atherosclerotic risk, but also the biochemical composition of blood flow may affect that 
severely. In terms of atherosclerosis, it was observed that the presence of inflammatory 
factors such as tumor necrosis alpha can modulate the values of the disease’s biomarkers. The 
inflammatory cytokine TNF-α provoked global expression of VCAM-1 independently of flow 
regime, and triggered monocyte adhesion to endothelial cells, inexistent without it. Only Ox-
LDL uptake remained unaffected by the presence of the inflammatory stimuli. In terms of 
thrombosis, TNF-α did not significantly modify TF expression by SMC, but uremic serum and 
some solutes did. In particular, uric acid, indoxil acetate and indoxil sulfate considerably 
augmented TF and thrombogenicity registers in SMC. This finding links the 6-fold increase in 
stent thrombosis in patients with chronic renal disease with the solutes’ concentration in 
uremic serum and offers novel stent thrombosis risk predictors for these patients. 
 
Integrated frameworks such as the one described in this thesis could be very useful in a range 
of biomedical fields. As an in vitro tool, our platform allows for a set of flow- and biochemical- 
related experiments that may help researchers to answer an array of biological and clinically 
relevant questions. The model can be extended to any bifurcated geometry, not only vascular, 
but respiratory or urinary as well, and represents an improvement from existing approaches. 
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Physicians may use it to refine the adequate treatments and adapt them to the individual state 
and vascular geometries of each patient and hence prevent flow- and drug-related post-
implantation complications. The platform is also a cheap, reproducible, and flexible tool to 
test medical devices such as stents or balloons and could help pharmaceutical companies by 
limiting the amount of in vivo assays done on development of such devices. The platform holds 
the capacity to cast bio-implantable vascular grafts in a close future. Current engineering 
techniques already allow direct 3D printing of arterial bifurcations using biocompatible 
materials such as collagen-based matrices. Once the geometry of the patient had been 
studied, the casted implant would have the optimal fluid dynamic conditions to minimize the 
graft’s risks like thrombosis or restenosis. The platform holds the capacity to cast 
bioimplantable vascular grafts in a close future 
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